БИОРЕЗОРБИРУЕМЫЙ ПЕРЕВЯЗОЧНЫЙ МАТЕРИАЛ ДЛЯ РАН

Изобретение относится к медицине и представляет собой нетканый материал для доставки GDF-5-родственного белка, содержащий волокна волокнистого сырьевого материала, включающие биорезорбируемые и/или биосовместимые полимеры, причем эти волокна содержат GDF-5-родственный белок, включающий цистин-узел-домен с идентичностью аминокислот по меньшей мере 60% относительно 102 аа-цистин-узел-домена GDF-5 человека, соответствующих аминокислотам 400-501 SEQ ID NO: 2. Указанный GDF-5-родственный белок распределен в волокнах. Изобретение относится также к повязке для ран, прокладке для ран и импланту, которые содержат указанный нетканый материал. 4 н. и 13 з.п. ф-лы, 9 ил., 4 пр.

РАЗЛАГАЕМАЯ КРОВООСТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ

ГЕМОСТАТИЧЕСКОЕ БИОЛОГИЧЕСКИ АБСОРБИРУЕМОЕ УСТРОЙСТВО С ПОЛИЭТИЛЕНГЛИКОЛЕМ В КАЧЕСТВЕ СВЯЗУЮЩЕГО ВЕЩЕСТВА

Гемостатическая прокладка, содержащая биологически абсорбируемый каркасный материал; порошок лиофилизированного тромбина, порошок лиофилизированного фибриногена и порошок плавкого связующего вещества, причем все порошки размещены на биологически абсорбируемом каркасном материале. Плавкое связующее вещество, такое как PEG, связывает порошок лиофилизированного тромбина и порошок лиофилизированного фибриногена с биологически абсорбируемым каркасным материалом для улучшения характеристик осыпаемости, смачиваемости и эффективности при применении, таком как гемостатическое лечение или уплотнение тканей в месте расположения раны. 11 з.п. ф-лы, 3 ил., 3 табл.

РАЗЛАГАЕМАЯ КРОВООСТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ

MESO-LACTID UND VERFAHREN ZU SEINER HERSTELLUNG.

MATERIAL AUS KARBOXYLGRUPPEN ENTHALTENDEN POLYSACCHARIDEN, SOWIE VERFAHREN ZUR HERSTELLUNG SOLCHER POLYSACCHARIDE.

RESORBIERBARES CHIRURGISCHES MATERIAL

Eine Methode zur Herstellung bioabbaubarer Materialien als Nasenhöhlenfüllung

Eine Methode zur Herstellung von bioabbaubaren Materialien als Nasenhöhlenfüllung weist die folgenden Schritte auf: a. Gleichmäßiges Mischen von Chitosan und Substrat (Stärke oder Cellulose) in einem vorbestimmten Temperaturbereich, um eine erste Lösung zu erzeugen; b. Hinzufügen von Vernetzer in die erste Lösung für Vernetzungsreaktion; c. Gießen der ersten Lösung in die Form; d. Entfernen vom Wasser durch Gefriertrocknung, wodurch die bioabbaubaren Materialien zum Füllen der Nasenhöhlen gewonnen werden. Die bioabbaubaren Materialien werden in die Nasenhöhle des Patienten gefüllt, um Blutung zu stoppen, wobei aufgrund der biologischen Abbaubarkeit eine zweite Verletzung beim Entfernen der Materialen vermieden wird.

Verbandsmaterial fuer Wunden

Hydrogels

Haemostatic pad

A haemostatic material 2 for stemming blood loss from a wound is mounted on a carrier layer 6, preferably by adhesive. The carrier may be a non-woven viscose material, woven gauze, a film, foam or sheet gel. The adhesive may form a separate layer 4 or it may be mixed with the haemostat (8, figure 2). The haemostatic material may be protected by a release layer (10, figure 3) and may be mounted on both sides of the carrier layer (figure 4). The haemostat may be biodegradable in the body and is preferably a polysaccharide or chitosan salt such as chitosan succinate in the form of granules of more than 74 microns diameter or short fibres of less than 7.5 mm length. It may include a medical surfactant such as lauric acid and an inert material such as alginate.

Improvements in or relating to wound dressings

A dressing for wounds involving loss of tissue, especially defects or cavities in hard tissues such as bones or teeth, comprises a body or solid substance to be fitted or packed into the defect or cavity in the wounded tissue to heal it, which body or substance is of a resorbable nature, devoid of animal protein in the native state and compatible with the tissue to be healed and is interwoven with pores or canals of ultracapillary nature which stimulate the ultracapillary system of the lost tissue, whereby the reticular stroma and blood plasma circulation interrupted in the wound surfaces may invade said pores or canals to promote healing. According to the invention, dentine and dental enamel are living tissues nutrified by "ultracapillaries" emanating from the blood capillaries of the tooth pulp and the blood plasma circulation in the wound region is artificially restored by filling with a resorbable material forming a circulation system similar to that of the natural system of ultracapillaries ...

A ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix and a method of manufacturing thereof

A ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix with high flexibility and absorbent capacity, wherein said sponge is porous by having interconnected vesicular micro-voids for holding or encapsulating therapeutic agents/drugs/cells inside, and wherein said sponge is obtained by lyophilizing a blend of polymers. Preferably, at least one of the polymers is in powdered form. The polymers may be selected from gelatin, chitosan, alginate, polyvinyl alcohol, polyvinyl chloride, polyethylene glycol and/or synthetic or naturally derived molecules including mucilaginous polysaccharides. The mucilaginous polysaccharides may be obtained from plant sources, for example Irish moss, marshmallow roots, fenugreek seed, flax seeds or psyllium husk seed. The sponge matrix is preferably in the form of a plug, tampon or sheet. Also disclosed is a method of making the porous sponge matrix, the method comprising sequentially blending the polymers together, blending ...

BLUTSTILLENDER SURGICAL FELT AND PROCEDURE FOR ITS PRODUCTION

Procedure for the production of sanitary products according to actually well-known methods from fiber courses

CO-ORDINATING POLYMER SYSTEM FOR USE WITH A MEDICAL DEVICE

Oxygen-generating compositions for enhancing cell and tissue survival in vivo

A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Bioresorbable wound dressing

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics.

Hemostatic sponge

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

Calcium-modified oxidized cellulose hemostat

Multi-component electrospun fiber scaffolds

A scaffold may comprise a first polymeric electrospun fiber comprising a first material having a first degradation rate, and a second polymeric electrospun fiber comprising a second material having a second degradation rate different from the first degradation rate. The first degradation rate may substantially correspond to a cell infiltration rate, and the second degradation rate may be slower than the first degradation rate. Such a scaffold may be manufactured by electrospinning a first polymer fiber having a first degradation rate by ejecting a first polymer solution from a first polymer injection system onto a mandrel, and electrospinning a second polymer fiber having a second degradation rate different from the first degradation rate by ejecting a second polymer solution from a second polymer injection system onto a mandrel. Wound healing may be improved by applying such a scaffold to a portion of a wound.

Delivery product for topical compositions

Haemostatic material

Bilayered devices for enhanced healing

Disclosed herein is a multilayered wound dressing comprising a first layer; the first layer including channels that facilitate neovascularization of a wound; and a second layer in contact with the first layer, the second layer having the same or different chemical composition as the first layer; where the second layer comprises at least one surface that has a texture and the direction of the texture is operative to facilitate cell orientation and growth. A method includes forming a first layer of a polymeric material; forming a second layer of the same polymeric material as the first layer on the first layer; and forming a textured surface of the second layer of the same polymeric material as the first layer, the textured surface being operative to facilitate directional cell growth when used in a wound dressing, where the first layer and the second layer are formed using an additive manufacturing process.

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

HEMOSTATIC SPONGE

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing.

TISSUE ABSORBABLE POLYMER SPONGE

METHOD FOR PREPARING A HAEMOSTATIC COMPOSITION

The present disclosure relates to a method for preparing a haemostatic composition comprising thrombin, the method comprising the step of reconstituting a dry thrombin directly in a paste, such as a paste comprising a biocompatible polymer. The haemostatic composition comprising thrombin may be prepared from a dry thrombin composition and a paste in a single step operation and be used for treatment of a wound.

MODIFIED BIODEGRADABLE POLYMERS, PREPARATION AND USE THEREOF FOR MAKING BIOMATERIALS AND DRESSINGS

L'invention concerne un procédé de préparation en milieu aqueux d'un polymère biodégradable modifié comprenant au moins deux étapes. La première de celles- ci est une étape de réaction entre un aminoacide, un peptide ou un polypeptide et I'anhydride maléique pour former un composé ayant une fonction acide vinyl- carboxylique insature. Dans la seconde étape de réaction, le diacide insature obtenu a la première étape est mis en réaction avec un polymère biodégradable ayant au moins une fonction amine primaire, tel une protéine fibreuse ou un glycosaminoglycane. Le polymère préférentiellement utilisé est du collagène ou du chitosane. L'invention concerne également le polymère biodégradable modifié obtenu avec ce procédé. L'invention concerne de plus un biomatériau ou un pansement contenant le polymère biodégradable modifié ayant des propriétés biocompatibles, cyto-compatibles, hémostatiques, bactéricides et cicatrisantes, et son usage médical, biomédical, pharmaceutique ou cosmétique.

SYSTEMS AND METHODS OF STIMULATION AND ACTIVATION OF FLUIDS FOR USE WITH INSTILLATION THERAPY

Systems and methods of stimulating or activating fluids for use in wound treatment systems.

REACTIVE OXIDATIVE SPECIES GENERATING MATERIALS AND METHODS OF USE

Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.

ADHESIVE ARTICLES CONTAINING A COMBINATON OF SURFACE MICROPATTERNING AND REACTIVE CHEMISTRY AND METHODS OF MAKING AND USING THEREOF

Adhesive articles containing microtopography, such as microprotrusions, and a coating of adhesive glue, such an adhesive having known toxicity and/or tissue reactive functional groups are described herein. The articles described herein contain a substrate, a plurality of micro features, and an adhesive, such as an adhesive glue. The articles described herein exhibit a 90° pull off adhesion of at least about 1.5 N/cm2. The articles described herein can contain less adhesive than when the adhesive is used alone without microtopography and yet exhibit equivalent adhesive strength with little or no toxicity or other adverse side effects (e.g., exothermic reaction).

COMPOSITE MATERIAL HAVING ABSORBABLE AND NONABSORBABLE COMPONENTS

... 30,286 TITLE Composite Material Having Absorbable And Nonabsorbable Components The invention is a composite material of two or more biocompatible polymers, at least one of which is poly-tetrafluoroethylene (PTFE) and one of which is a bioabsorbable polymer. The nonabsorbable PTFE is used in the composite as a reinforcing binder. The reinforcing binder is a network of unsintered, interconnected micro-fibers which are formed, for example, by blending with a thermoplastic polymer vehicle, such as polymethylmethacrylate which is subsequently extracted. The bioabsorbable component is contained within the structure of the PTFE microfibrils. This composite is useful in the repair of mammalian tissue where tissue ingrowth and permanent support is required.

BIOABSORBABLE WOUND IMPLANT MATERIALS

JJM-28 14 BIOABSORBABLE WOUND IMPLANT MATERIALS Heteromorphic sponges are described which have matrix structures with oriented substructures added to facilitate cellular invasion. A sponge may be used as a wound implant by cutting it to the shape of a wound bed and placing therein. The matrix structure provides conduits which assist invasion of the sponge by cells which degrade the sponge and lay down new tissue to replace it. The incorporation of active agents in the matrix and/or substructures enhances wound healing.

Verfahren zur Herstellung von Trägern für Arzneimittel.

Verfahren zur Herstellung von Blut oder andere Sekrete adsorbierenden resorbierbaren Schwämmen aus gelbildenden Proteinen, wie z. B. Gelatine.

Verfahren zur Behandlung von Flächengebilden aus faserhaltigem Zellulosematerial

Verfahren zur Herstellung eines absorbierbaren Hämostatikums

Pansement pour blessures

[...][...].

Process for the preparation of polysaccharide derivatives

Polysaccharide derivatives which can be absorbed by body tissues are prepared. These derivatives are obtained by treating a substituted polysaccharide with an acidic or alkaline medium and then heating the treated material at elevated temperature until the material displays reductive capacities of at least 15. The resulting polysaccharide derivatives can be used as lubricants for surgical gloves.

HEMOSTATIC PATCH AND METHOD OF PREPARATION

La présente invention porte sur un patch hémostatique comprenant une couche poreuse à base de cellulose oxydée et un film neutralisé à base de chitosane, ledit film comprenant une face libre et une face fixée à une des faces de la couche poreuse, et sur le procédé de préparation d'un tel patch comprenant les étapes suivantes : - a°) préparation d'une couche poreuse à base de cellulose oxydée, - b°) préparation d'un film à base de chitosane à partir d'une solution aqueuse acide de chitosane, - c°) fixation du film obtenu en b°) à une face de la couche poreuse, - d°) neutralisation du film obtenu en b°), - l'étape c°) pouvant être réalisée avant ou après l'étape d°), caractérisé en ce que : l'étape d°) de neutralisation comprend le traitement dudit film avec une composition neutralisante comprenant au moins de l'éthanol et de l'hydroxyde d'ammonium (NH4OH).

Process intended to prevent the tearing and the felting of the medical, and produced paper products obtained for the implementation of this process

KNIT TEXTILE STRUCTURE DIFFERENTIATED AREAS

Cette structure textile tricotée est obtenue par la technologie à maille jetée sur métier chaîne, Rachel ou crochet, en une seule étape. Elle comprend une zone centrale (101) délimitée par une zone périphérique (102), lesdites zones présentant des densités différentes et/ou des caractéristiques mécaniques différentes.

SILICA SOL MATERIAL HAVING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE FOR PRODUCING BIOLOGICALLY DEGRADABLE AND/OR RESORBABLE SILICA GEL MATERIALS FOR HUMAN MEDICINE AND/OR MEDICAL TECHNOLOGY

The invention relates to a novel silica sol material having at least one therapeutically active substance, and the use thereof for producing biologically resorbably and biologically degradable silica gel materials having improved properties. The materials, such as fibers, non-woven mats, powders, monoliths, and/or coatings are used, for example, in medical technology and/or human medicine, particularly for wound treatment.

ANTIMICROBIAL RELEASING POLYMERS

The present disclosure is directed to polymers having hydroxyl containing bioactive agents incorporated into the backbone of the polymer or attached thereto by pendant linkages. Hydroxyl containing bioactive agents which may be attached to these polymers include antimicrobial agents such as triclosan. The polymers may be utilized to form medical devices or coatings for such devices. The hydroxyl containing bioactive agent may be released from the polymer upon hydrolysis of the polymeric backbone or pendant linkage in vivo.

SYSTEMS AND METHODS FOR DELIVERING AN AGENT TO A WOUND UNDER NEGATIVE PRESSURE

The invention provides biodegradable compositions and methods for using such biodegradable compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

RESORBABLE MEMBRANE

The present invention relates to resorbable membranes for medical uses. The membranes according to the present invention are produced or producible from a composition comprising at least one polyol component, at least one polyisocyanate componentand an additive selected from polyvinylpyrrolidone, polyvinyl- polypyrrolidone, a copolymer of polyvinylpyrrolidone with vi- nylacetate, vinylimidazole or vinylcaprolactam or mixtures thereof. The present invention further relates to a kit comprising a multitude of membranes with different absorption rates.

SYSTEMS AND METHODS OF STIMULATION AND ACTIVATION OF FLUIDS FOR USE WITH INSTILLATION THERAPY

Systems and methods of stimulating or activating fluids for use in wound treatment systems. 1. A wound treatment system comprising:a wound dressing;a fluid storage device configured to deliver a fluid to the wound dressing, wherein the fluid comprises molecules with a protective coating; andan energy source configured to direct ultrasonic energy to the fluid and to degrade the protective coating and to activate a therapeutic property of the fluid.2. (canceled)3. (canceled)4. The wound treatment system of claim 1 , wherein the energy source is configured to activate a component of the fluid that degrades the protective coating.5. The wound treatment system of claim 1 , wherein the protective coating comprises a bioabsorbable glass.6. The wound treatment system of claim 1 , wherein the protective coating comprises a ceramic.7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. The wound treatment system of claim 1 , wherein the energy source is configured to direct energy to the fluid proximal to the wound dressing.13. The wound treatment system of claim 1 , further comprising a conduit in fluid communication with the fluid storage device and the wound dressing.14. The wound treatment system of claim 13 , wherein the energy source is configured to direct energy to the fluid in the conduit.15. The wound treatment system of claim 1 , wherein the therapeutic property includes an anti-biotic property.16. The wound treatment system of claim 1 , wherein the therapeutic property includes an analgesic property.17. The wound treatment system of claim 1 , wherein the therapeutic property aids with debridement of tissue.18. The wound treatment system of claim 1 , wherein the therapeutic property improves the ability to remove the wound dressing from a wound.19. The wound treatment system of claim 1 , wherein the therapeutic property reduces biofilm buildup in a wound.20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. ( ...

Method for promoting growth of new connective tissue over surface wounds

Method for promoting the growth of new connective tissue over a surface wound wherein at least a portion of the epithelium has been damaged or removed. The method comprises coating the wound with a composition consisting essentially of a connective tissue promoting agent selected from the group consisting of: (1) pulverized absorbable gelatin sponge, (2) aminocaproic acid, (3) a compound of the formula 4NH2CH2(CH2)4COOH.CaX2 wherein X is chloride or bromide, or (4) mixtures thereof, said composition being present in an amount sufficient to produce new connective tissue over the surface wound. The process is particularly useful for treating both contaminated and uncontaminated, denuded, ulcerated, and/or burned tissue.

Collagen-thrombin compositions

A method of forming a collagen-thrombin hemostatic composition is comprised of forming a homogeneous aqueous admixture of collagen and thrombin at a basic pH and lyophilizing the collagen-thrombin admixture to form a stable collagen sponge having thrombin therein. The collagen utilized in the process is absorbable when placed in vivo. Additionally, a lyophilized collagen product is comprised of collagen which is absorbable when placed in vivo and thrombin distributed within the collagen. The collagen product is storage stable.

Medical devices fabricated from copolymers having recurring carbonate units

This invention relates to medical devices formed totally or in part from homopolymers or copolymers comprising recurring carbonate moieties.

BIOCOMPATIBLE, FLEXIBLE, HAEMOSTATIC SHEET

The invention relates to a biocompatible, flexible, haemostatic sheet comprising:

PENDANT HYDROPHILE BEARING BIODEGRADABLE COMPOSITIONS AND RELATED DEVICES

Heteromorphic sponges containing active agents

БИОСОВМЕСТИМЫЙ ГИБКИЙ ГЕМОСТАТИЧЕСКИЙ ЛИСТ

Группа изобртений относится к биосовместимому гибкому гемостатическому листу, содержащему: водостойкую структуру когезивного волокнистого носителя, содержащую трехмерное взаимосвязанное внутреннее пространство, указанная структура волокнистого носителя содержит волокна, содержащие нуклеофильный полимер, несущий химически активные нуклеофильные группы, которым является сополимер поли(2-этил/аминоэтиламидоэтил-2-оксазолина) (NU-POx); и распределенное во внутреннем пространстве множество реакционно-способных полимерных частиц, содержащих водорастворимый электрофильный полимер - терполимер поли[2-(этил/гидрокси-этил-амид-этил/NHS-сложный эфир-этил-сложный эфир-этил-амид-этил)-2-оксазолина] с активированной NHS-боковой цепью, содержащей 20% NHS-сложноэфирных групп, несущий, по меньшей мере, три химически активных электрофильных группы, которые могут взаимодействовать с аминовыми группами в ткани и крови, а также с реакционно-способными нуклеофильными группами нуклеофильного полимера, с образованием ...

ВЫДЕЛЯЮЩИЙ ЛЕКАРСТВЕННОЕ СРЕДСТВО МАТЕРИАЛ ХИРУРГИЧЕСКОГО ИМПЛАНТАТА ИЛИ ПЕРЕВЯЗОЧНОГО МАТЕРИАЛА

Материал для хирургического имплантата или наружного перевязочного материала, который действует и как кровоостанавливающее средство, и как средство для безопасной и эффективной доставки с контролируемой скоростью любого из множества фармацевтических препаратов к намеченной ткани. Материал содержит носитель в виде волокон, шовных материалов, тканей, твердых вспененных материалов с поперечными связями или бинтов, фармацевтический препарат в виде твердых микрочастиц, связанных с волокнами носителя с возможностью выделения с них, и липидно-вспомогательное средство, которое способствует связыванию микрочастиц с волокнами, а также их действию в организме. 2 с. и 22 з. п. ф-лы, 2 табл., 3 ил.

ГЕМОСТАТИЧЕСКОЕ БИОЛОГИЧЕСКИ АБСОРБИРУЕМОЕ УСТРОЙСТВО С ПОЛИЭТИЛЕНГЛИКОЛЕМ В КАЧЕСТВЕ СВЯЗУЮЩЕГО ВЕЩЕСТВА

Гемостатическая прокладка содержит биологически абсорбируемый каркасный материал, порошок лиофилизированного тромбина, порошок лиофилизированного фибриногена и полиэтиленгликоль. Частицы тромбина и фибриногена распределены на биологически абсорбируемом каркасном материале. Полиэтиленгликоль связывает частицы тромбина и частицы фибриногена с биологически абсорбируемым каркасным материалом прокладки. Полиэтиленгликоль имеет среднюю молекулярную массу от 1000 до 20000 Дальтон. Также описан способ производства гемостатической прокладки и способ гемостатической обработки раневой области. Гемостатическая прокладка по изобретению имеет улучшенные характеристики осыпаемости и гемостатические характеристики. 3 н. и 16 з.п. ф-лы, 3 ил., 3 табл., 6 пр.

КИЗЕЛЬЗОЛЬ-МАТЕРИАЛ ПО МЕНЬШЕЙ МЕРЕ С ОДНИМ ТЕРАПЕВ-ТИЧЕСКИ АКТИВНЫМ ВЕЩЕСТВОМ ДЛЯ ПОЛУЧЕНИЯ БИОЛОГИЧЕ-СКИ РАЗЛАГАЕМЫХ И/ИЛИ ВПИТЫВАЕМЫХ КИЗЕЛЬГЕЛЬ-МАТЕРИАЛОВ ДЛЯ МЕДИЦИНЫ ЧЕЛОВЕКА И/ИЛИ МЕДТЕХНИКИ

Изобретение относится к новому кизельзоль-материалу по меньшей мере с одним терапевтически активным веществом для получения биологически разлагаемых и впитываемых кизельгель-материалов. Предложен кизельзоль-материал по меньшей мере с одним терапевтически активным веществом, полученный реакцией гидролиза-конденсации тетраэтоксисилана, катализируемой кислотами при начальном значении рН от 0 до ≤7 в присутствии водорастворимого растворителя в течение по меньшей мере 16 часов при температуре 0-80°С; последующим упариванием с получением однофазного раствора; охлаждением полученного раствора с последующим созреванием при температуре 2-4°С с образованием гомогенного однофазного золя. Добавление локального анестетика проводят на одной из описанных стадий. Предложены также варианты применения указанного кизельзоль-материала и получаемые из него биологически впитываемый или биоактивный порошок, монолит или покрытие и биологически разлагаемый или биологически впитываемый волокнистый материал. Технический ...

БИОРАЗРУШАЕМЫЙ МАТЕРИАЛ И СПОСОБ ПОЛУЧЕНИЯ БИОРАЗРУШАЕМОГО МАТЕРИАЛА

Изобретение относится к биоразрушаемому материалу. Биоразрушаемый материал, который представляет собой сшитый поперечными химическими связями продукт, образован мультивалентным соединением A, включающим 3 или более функциональных групп X, выбранных из группы, состоящей из гидроксильной группы, тиольной группы и аминогруппы, и мультивалентным соединением B, включающим 3 или более функциональных групп Y, выбранных из группы, состоящей из карбоксильной группы, изоцианатной группы и тиоизоцианатной группы, где поперечная химические связи сформированы с помощью реакции конденсации указанной функциональной группы (групп) X и указанной функциональной группы (групп) Y, где величина (y+z)/(x+z) имеет значение от 1,2 до 4,0, если MA≥MB, и величина (x+z)/(y+z) имеет значение от 1,2 до 4,0, если MA Подробнее

МЕДИЦИНСКОЕ ИЗДЕЛИЕ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

Группа изобретений относится к области создания медицинских изделий. Медицинское изделие в форме накладки на рану из нетканого материала, включает ротационно спряденные волокна, которые содержат по меньшей мере один синтетический и биорезорбируемый полимер и по меньшей мере один гидрофильный и/или тканеадгезивный полимер. При этом изделие содержит слои ротационно спряденных волокон, которые отличаются друг от друга по доле в волокнах по меньшей мере одного синтетического и биорезорбируемого полимера и/или по меньшей мере одного гидрофильного и/или тканеадгезивного полимера. Также раскрывается способ изготовления медицинского изделия. Группа изобретений обеспечивает возможность изготавливать многофункциональные, в частности бифункциональные, медицинские изделия, которые могут быть универсально использованы в области медицины. 2 н. и 15 з.п. ф-лы, 14 пр.

МАТЕРИАЛ ДЛЯ ПРЕДОТВРАЩЕНИЯ ПОЯВЛЕНИЯ СПАЕК

МЕДИЦИНСКОЕ ИЗДЕЛИЕ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

БИОРАЗЛАГАЕМЫЙ НЕТКАНЫЙ МАТЕРИАЛ ДЛЯ МЕДИЦИНСКИХ ЦЕЛЕЙ

... 1. Биоразлагаемый нетканый материал, содержащий:(i) по меньшей мере один полимер для индуцирования первичного гемостаза;(ii) по меньшей мере один непротеиногенный низкомолекулярный водорастворимый активатор вторичного гемостаза и(iii) по меньшей мере один непротеиногенный низкомолекулярный водорастворимый ингибитор фибринолиза.2. Биоразлагаемый нетканый материал по п. 1, отличающийся тем, что нетканый материал содержит по меньшей мере одно противоинфекционное активное вещество.3. Биоразлагаемый нетканый материал по п. 1 или 2, отличающийся тем, что нетканый материал содержит волокна (1), причем волокна (1) нетканого материала содержат (i) по меньшей мере один полимер для индуцирования первичного гемостаза, (ii) непротеиногенный низкомолекулярный водорастворимый активатор вторичного гемостаза, (iii) непротеиногенный низкомолекулярный водорастворимый ингибитор фибринолиза и/или при необходимости по меньшей мере одно противоинфекционное активное вещество.4. Биоразлагаемый нетканый материал ...

МАТЕРИАЛЫ, ГЕНЕРИРУЮЩИЕ РЕАКЦИОННОСПОСОБНЫЕ ОКИСЛИТЕЛЬНЫЕ ЧАСТИЦЫ, А ТАКЖЕ СПОСОБЫ ИХ ПРИМЕНЕНИЯ

... 1. Биосовместимый материал, включающий по меньшей мере один полукристаллический, гидролитически разлагаемый полимер, подвергнутый воздействию ионизирующего излучения при общей дозе от приблизительно 30 до приблизительно 50 кГрэй, где указанный биосовместимый материал содержит стабилизированные свободные радикалы.2. Биосовместимый материал по п. 1, при контактировании которого с водной средой стабилизированные свободные радикалы обеспечивают получение реакционноспособных окислительных частиц в течение длительного периода времени.3. Биосовместимый материал по п. 1, где удельная площадь поверхности на единицу площади биосовместимого материала составляет от приблизительно 0,001 м/г до приблизительно 50 м/г.4. Биосовместимый материал по п. 1, где полимер подвергнут воздействию ионизирующего излучения при общей мощности дозы от приблизительно 40 кГрэй до приблизительно 50 кГрэй.5. Биосовместимый материал по п. 1, в котором полимер является биологически рассасывающимся.6. Биосовместимый материал ...

ГЕМОСТАТИЧЕСКОЕ БИОЛОГИЧЕСКИ АБСОРБИРУЕМОЕ УСТРОЙСТВО С ПОЛИЭТИЛЕНГЛИКОЛЕМ В КАЧЕСТВЕ СВЯЗУЮЩЕГО ВЕЩЕСТВА

... 1. Гемостатическая прокладка, содержащая:a) биологически абсорбируемый каркасный материал,b) порошок лиофилизированного тромбина,c) порошок лиофилизированного фибриногена, иd) порошок плавкого связующего вещества,причем указанные порошки тромбина и фибриногена распределены на биологически абсорбируемом каркасном материале и порошок плавкого связующего вещества связывает порошок тромбина и порошок фибриногена с биологически абсорбируемым каркасным материалом.2. Гемостатическая прокладка по п. 1, в которой плавкое связующее вещество полностью не обволакивает порошок лиофилизированного тромбина и/или лиофилизированного фибриногена, и причем плавкое связующее вещество является гидрофильным, биологически совместимым и биологически абсорбируемым материалом, имеющим температуру плавления от приблизительно 25°C до приблизительно 100°C.3. Гемостатическая прокладка по п. 2, в которой плавкое связующее вещество содержит полимер полиэтиленгликоля, имеющий среднюю молекулярную массу от приблизительно ...

Перевязочный материал для ран

Verfahren,um unerwuenschte Auflockerung oder Verfilzung von Papier zu verhindern,welches bei Hygienwaren od.dgl. Verwendung findet

POLYESTERHYDROGELE

Chirurgisches Implantat

Ein chirurgisches Implantat (20) beinhaltet eine flexible Basisstruktur (22) mit einer Fläche und mehrere resorptionsfähige Folienstücke (26), die an der Fläche der Basisstruktur (22) befestigt sind. Jedes Folienstück (26) beinhaltet mehrere massive Vorsprünge (28), die von dem jeweiligen Folienstück (26) in einer Richtung weg von der Basisstruktur (22) hervortreten.

BIOLOGISCH ABBAUBARES ABSORPTIONSMATERIAL

Die vorliegende Erfindung offenbart ein Verfahren zur Herstellung eines biologisch abbaubaren Absorptionsmaterials, umfassend die folgenden Schritte: (1) Herstellen eines oberflächenschichtigen hydrophilen Vliesstoffs; (2) Herstellen eines biobasierten wasserabsorbierenden Harzes durch Aufnahme eines Hanfgarns als Rohstoff; (3) Hinzufügen von Glycerinstearat in das erhaltene biobasierte wasserabsorbierende Harz und Extrusionsformen des Resultierenden zur Herstellung eines Kernschichtmaterials; und (4) Abdecken der Oberfläche des Kernschichtmaterials mit dem oberflächenschichtigen hydrophilen Vliesstoff und Heißpressen zum Verschmelzen, um das biologisch abbaubare Absorptionsmaterial herzustellen.

Bioresorbable alginate derivatives

Solid polysaccharide materials for use as wound dressings

A ready-to-use, hydrophilic, self-dispersive, fragmentable and biodegradable porous sponge matrix and a method of manufacturing thereof

WUNDVERBANDMATERIALIEN WITH KOLLAGEN AND OXIDIZED CELLULOSE

BLUTSTILLENDER CHIRURGISCHER FILZ UND VERFAHREN ZU SEINER HERSTELLUNG

PROCEDURE FOR THE PRODUCTION CELEBRATIONS OF A FEDERATION FOR THE TREATMENT OF INJURED FABRIC

MATERIAL FROM KARBOXYLGRUPPEN CONTAINING POLYSACCHARIDEN, AS WELL AS PROCEDURE FOR THE PRODUCTION OF SUCH POLYSACCHARIDE.

DURABLE HYDROPHILIC TREATMENT FOR A BIODEGRADABLE POLYMERIC SUBSTRATE

Hemostatic wound dressing containing proteinaceous polymers

Wound implant materials

Biomedical foams

Surgical implant

A surgical implant (20) comprises a flexible basic structure (22) having a face and a plurality of resorbable film pieces (26) attached to the face of the basic structure (22). Each film piece (26) comprises a plurality of solid protrusions (28) emerging from the respective film piece (26) in a direction away from the basic structure (22).

MULTI-COMPONENT ELECTROSPUN FIBER SCAFFOLDS

A scaffold may comprise a first polymeric electrospun fiber comprising a first material having a first degradation rate, and a second polymeric electrospun fiber comprising a second material having a second degradation rate different from the first degradation rate. The first degradation rate may substantially correspond to a cell infiltration rate, and the second degradation rate may be slower than the first degradation rate. Such a scaffold may be manufactured by electrospinning a first polymer fiber having a first degradation rate by ejecting a first polymer solution from a first polymer injection system onto a mandrel, and electrospinning a second polymer fiber having a second degradation rate different from the first degradation rate by ejecting a second polymer solution from a second polymer injection system onto a mandrel. Wound healing may be improved by applying such a scaffold to a portion of a wound. See Fig. WO 2016/176559 PCT/US2016/030058 ...

ANTIOXIDANT WOUND DRESSING MATERIALS

... ²²²A wound dressing material comprising a solid bioabsorbable substrate dyed with ²an antioxidant dyestuff. The substrate may comprise collagen, chitosan or ²oxidized regenerated cellulose, and the dyestuff may for example be an aniline ²or acridine dye. The material preferably also comprises a silver salt, whereby ²the dyestuff stabilizes the silver salt. Also provided are methods of making ²such materials, and wound dressings comprising such materials.² ...

DEGRADABLE POLY(VINYL ALCOHOL) HYDROGELS

Biodegradable biocompatible hydrogels based on poly(vinyl alcohol) and methods for their preparation. The methods for preparation of the hydrogels involve the use of prepolymers. The prepolymers have a PVA backbone and pendant chains that include a polymerizable group. In one embodiment, the pendant chains also include a biodegradable region. In another embodiment, biodegradable regions are incorporated into the hydrogel during formation.

IMPROVED FIBRINOGEN-BASED TISSUE ADHESIVE PATCH

An improved fibrinogen-based tissue sealing patch having a degradation time of less than two weeks is disclosed. The patch comprises a polyethylene glycol-caprolactone-lactide (PEG- CL-LA) triblock copolymer film into which a fibrinogen-based sealant comprising less than 8 mg/cm 2 fibrinogen and less than 10 IU/cm 2 thrombin has been incorporated. In preferred embodiments, the polymer film comprises PEG having a molecular weight of between 3000 and 3500 and a CL:LA:PEG ratio of 34:2:1. Methods of production and use of the patch are also disclosed.

PROCESS FOR PREPARING BIOABSORBABLE SHEET PREPARATION HOLDING THROMBIN

Provided is a method of producing a bioabsorbable sheet preparation which comprises thrombin having been immobilized thereon. A method of producing a thrombin-immobilized bioabsorbable sheet preparation which comprises steps of dipping a bioabsorbable sheet comprising polyglycolic acid in a filling solution containing thrombin as the active ingredient, glycerol as a softening agent and Tween 80 as an infiltrating agent, optionally together with histidine and trehalose as stabilizers, drying the same and thus immobilizing thrombin on the bioabsorbable sheet as described above; and a thrombin-immobilized bioabsorbable sheet preparation obtained by the preceding method.

SILICA SOL MATERIAL HAVING AT LEAST ONE THERAPEUTICALLY ACTIVE SUBSTANCE FOR PRODUCING BIOLOGICALLY DEGRADABLE AND/OR RESORBABLE SILICA GEL MATERIALS FOR HUMAN MEDICINE AND/OR MEDICAL TECHNOLOGY

The invention relates to a novel silica sol material containing at least one therapeutically active ingredient and its use for the production of bioabsorbable and biodegradable silica gel materials with improved properties. The materials, such as, for example, fibers, fleeces, powder, monolith and/or coating are employed, for example, in medical technology and/or human medicine, in particular for wound treatment.

FOAMS FOR OXYGEN DELIVERY TO WOUNDS

There is provided a composition comprising covalently linked segments of, for example, polycaprolactone and polyethylene glycol that are linked by a cross- linker. Such a composition foams in the presence of a catalyst and a solution containing an oxygen forming chemical like hydrogen peroxide. The foamed composition retains oxygen for delivery to, for example, a wound, where it aids in healing.

SURGICAL IMPLANT

A surgical implant (20) comprises a flexible basic structure (22) having a face and a plurality of resorbable film pieces (26) attached to the face of the basic structure (22). Each film piece (26) comprises a plurality of solid protrusions (28) emerging from the respective film piece (26) in a direction away from the basic structure (22).

WOUND HEALING MATERIAL

A device for use in promoting wound healing (including wounds caused by accident, surgery or disease) comprises a substrate formed of a biologically acceptable material, e.g. a polymer which biodegrades in vivo, which has thereon means capable of orienting cell growth so as to allow guided tissue repair and to encourage regeneration of tissue of normal function and morphology. The substrate may be a thin polymer sheet stamped or embossed with a series of grooves of typical dimensions 1 to 10 microns wide and 1-10 microns deep. The sheet may be folded or rolled into a three-dimensional shape before insertion into the wound.

A RAW MEMBRANOUS MATERIAL FOR MEDICAL MATERIALS AND MANUFACTURING METHODS THEREOF

Disclosed is a raw membrane material for medical materials, which is of acellular nature and consists essentially of a compact layer with a characteristic matrix structure retained and which is produced by dissolving and removing cellular layers including epithelium and fibroblast layers from biogenic connective tissue membrane which comprises epithelial, basement membrane, compact and fibroblast layers. To remove epithelium and fibroblast layers, biogenic connective tissue is treated with an aqueous solution of a quaternary ammonium salt of the formula: ¢C6H5CH2N(CH3)2R!+Cl- (wherein R is an alkyl group of 8 to 18 carbon atoms) and then with thiolprotease which is a glycoprotein and has a molecular weight of about 26,000 and an isoelectric point of 9 and thereafter is subjected to ultrasonic washing. The membrane material, when used in the medical field, stimulates the growth of tissue cells and is decomposed and absorbed in living body as damaged tissues regenerate.

AN ADJUNCTIVE POLYMER SYSTEM FOR USE WITH MEDICAL DEVICE

A medical device which is a surgically implantable device coated with an adjunctive polymer system. The adjunctive polymer system forms a solid matrix when introduced into a human or animal body. The adjunctive polymer system can contain a drug or a medicament which is released over time from the solid matrix. The adjunctive polymer system contacts body tissue into which the surgically implantable device is implanted.

COATED BIOABSORBABLE BEADS FOR WOUND TREATMENT

The invention provides a material for use in a wound dressing or wound implant, the material comprising a plurality of beads, wherein each bead comprises a porous core of a first bioabsorbable material and a substantially non-porous layer of a second bioabsorbable material around the core. The porous core is preferably a sponge formed by freeze-drying a liquid suspension of the first bioabsorbable material. The preferred diameter of the beads is 0.1-4.0 mm, and the beads are preferably dispersed in a liquid or solid matrix. The invention also provides a method of making beads for use in the materials of the invention.

POLYESTERAMIDE, ITS PREPARATION AND SURGICAL DEVICES FABRICATED THEREFROM

A polyesteramide suitable for use in the fabrication of absorbable surgical devices such as monofilament and multifilament sutures, films, sheets, plates, clips, staples, pins, screws, and the like, is obtain ed by reacting a monoalkanolamine such as ethanolamine with a diacid halide such as succinic acidchloride to provide a diamidediol and thereafter reacting the diamidediol with the same or different diacid halide under polymerization conditions to form the polyesteramide.

Biomedical foams

Wound dressing materials

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Novel injectable chitosan mixtures forming hydrogels

A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

Resorbable Membrane

The present invention relates to resorbable membranes for medical uses. The membranes according to the present invention are produced or producible from a composition comprising at least one polyol component, at least one polyisocyanate component and an additive selected from polyvinylpyrrolidone, polyvinylpolypyrrolidone, a copolymer of polyvinylpyrrolidone with vinylacetate, vinylimidazole or vinylcaprolactam or mixtures thereof. The present invention further relates to a kit comprising a multitude of membranes with different absorption rates. 19-. (canceled)10. A resorbable membrane for medical applications produced or producable from a composition comprising:a. at least one polyol component comprising at least one compound with at least two, three or four hydroxyl groups;b. at least one polyisocyanate component or at least one polyurethane prepolymer comprising at least one compound with at least two, three or four isocyanate groups; andc. an additive comprising at least one of the following compounds: polyvinylpyrrolidone, polyvinylpolypyrrolidone, a copolymer of polyvinylpyrrolidone with vinylacetate, vinylimidazole or vinylcaprolactam or mixtures thereof.11. The resorbable membrane according to claim 10 , wherein the membrane has a thickness of between 10 μm and 1000 μm.12. The resorbable membrane according to claim 10 , wherein the at least one polyol component is present in an amount between 1 and 96% by weight.13. The resorbable membrane according to claim 10 , wherein the at least one polyisocyanate component or the at least one polyurethane prepolymer are present in an amount of between 4 and 60% by weight.14. The resorbable membrane according to claim 10 , wherein the additive c. is present in an amount of between 0.001 and 10% by weight.15. The resorbable membrane according to claim 10 , the polyvinylpyrrolidone has a molecular weight of between 7′000 and 1′000′000 g/mol.16. The resorbable membrane according to claim 10 , wherein the at least one ...

Nitric oxide-releasing compositions and methods

The invention relates to nitric oxide-releasing compositions comprising polyacrylonitrile polymers that are diazeniumdiolated, and to medical devices comprising such compositions, as well as to methods of making and using the compositions and medical devices.

COMPOSITES CONTAINING POLYPEPTIDES ATTACHED TO POLYSACCHARIDES AND MOLECULES

This document provides methods and materials related to composites or coatings containing polypeptides attached to polysaccharides and/or molecules. For example, methods and materials related to composites or coatings containing polypeptides (e.g., casein polypeptides) attached to polysaccharides (e.g., cellulose) and/or molecules (e.g., calcium containing molecules such as calcium phosphate and calcium carbonate and/or polyesters such as polylactic acid and polyhydroxybutyrate) are provided. A coating provided herein can include both cationic and ionic polymers, polypeptides, or polysaccharides. 120-. (canceled)21. A method for coating a product , wherein said method comprises:(a) combining casein, a calcium containing mineral, and a biopolymer to form a mixture, and(b) applying said mixture to a product to form a coated product.22. The method of claim 21 , wherein said calcium containing mineral is calcium carbonate.23. The method of claim 21 , wherein said calcium containing mineral is calcium phosphate.24. The method of claim 21 , wherein said biopolymer comprises polylactic acid.25. The method of claim 21 , wherein said biopolymer comprises poly(lactic-co-glycolic) acid.26. The method of claim 21 , wherein said step (a) comprises mixing said casein and said calcium containing mineral in water.27. The method of claim 21 , wherein said step (a) comprises mixing said casein and said calcium containing mineral in water having a pH of 7-11.28. The method of claim 21 , wherein said step (a) comprises mixing said casein and said calcium containing mineral in solution claim 21 , wherein the solid content of said solution is from 0.5 percent to 5 percent.29. The method of claim 21 , wherein said step (a) comprises (i) mixing said casein and said calcium containing mineral in solution and (ii) adding said biopolymer to said solution.30. The method of claim 21 , wherein said mixture is applied to said product using a gravure coating process.31. The method of claim 21 , ...

DRUG DELIVERY COMPOSITIONS AND METHODS

A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least one amino acid in an aqueous environment. A biodegradable fabric is disclosed which includes a polymerized structure of a triple salt proxy functional group and at least one amino acid functional group. 1. A drug delivery composition comprising a triple salt proxy functional group and at least one amino acid functional group , wherein the triple salt proxy functional group includes a peroxy moiety.2. The drug delivery composition of claim 1 , wherein the triple salt proxy functional group is KHSO.3. The drug delivery composition of claim 1 , wherein the amino acid functional group is selected from the group consisting of derivatives of glutamine claim 1 , alanine claim 1 , aspartic acid claim 1 , lysine claim 1 , glycine claim 1 , cysteine claim 1 , arginine claim 1 , proline claim 1 , naturally occurring peptides claim 1 , artificially occurring peptides claim 1 , and combinations thereof.4. The drug delivery composition of claim 1 , wherein the triple salt proxy functional group includes the property of broad spectrum antimicrobial activities against bacteria claim 1 , fungi and viruses.5. The drug delivery composition of claim 1 , wherein the drug delivery composition further comprises a plurality of amino acid functional groups.6. The drug delivery composition of claim 5 , wherein the plurality of amino acid functional groups further comprises amino acid health benefits.7. The drug delivery composition of claim 1 , wherein the drug delivery composition is a powder base material.8. The drug delivery composition of claim 7 , wherein the powder base material further comprises the property of rapid solubility in an aqueous solution.9. A method for forming a drug delivery composition comprising reacting a triple salt including a peroxy ...

BIOMEDICAL PATCHES WITH SPATIALLY ARRANGED FIBERS

A three-dimensional electrospun nanofiber scaffold for use in repairing a defect in a tissue substrate is provided. The three-dimensional electrospun nanofiber scaffold includes a first layer formed by a first plurality of electrospun polymeric fibers and a second layer formed by a second plurality of electrospun polymeric fibers. The second layer is coupled to the first layer using a coupling process and includes a plurality of varying densities formed by the second plurality of electrospun polymeric fibers. The first and second layers are configured to degrade via hydrolysis after at least one of a predetermined time or an environmental condition. The three-dimensional electrospun nanofiber scaffold is configured to be applied to the tissue substrate containing the defect. 120-. (canceled)21. A three-dimensional electrospun nanofiber scaffold for facilitating tissue repair , the three-dimensional electrospun nanofiber scaffold comprising:a first plurality of deposited electrospun polymeric nanofibers; anda second plurality of deposited electrospun polymeric nanofibers,the second plurality of deposited electrospun polymeric nanofibers being coupled to the first plurality of electrospun polymeric nanofibers,wherein at least some of the second plurality of deposited electrospun polymeric nanofibers are deposited over a portion of the first plurality of electrospun polymeric nanofibers to form one or more regions comprising a spatial variation between fibers on an outer surface of the three-dimensional electrospun nanofiber scaffold that is different from one or more other regions not on the outer surface of the three-dimensional electrospun nanofiber scaffold,wherein at least some of the second plurality of deposited electrospun polymeric nanofibers are commingled with the first plurality of electrospun polymeric nanofibers within the first portion,the three-dimensional electrospun nanofiber scaffold further comprising a surface, the surface comprising a surface ...

WOUND COVERINGS COMPRISING VITAMIN D AND RELATED METHODS

A wound covering is provided that comprises a substrate and vitamin D, or analogues or metabolites thereof, embedded in the substrate. Methods of making a wound covering are also provided and include the steps of providing a solution that includes a polymer; adding vitamin D, or analogues or metabolites thereof, to the solution to form a mixture; and forming one or more fibers from the mixture that are then embedded with the vitamin D, or analogues or metabolites thereof. Methods of treating a subject are further provided and include the step of applying a wound covering including one or more fibers embedded with vitamin D, or analogues or metabolites thereof, to a site on a subject. 1. A wound covering , comprising:a substrate; andvitamin D, or analogues or metabolites thereof, embedded in the substrate.2. The wound covering of claim 1 , wherein the substrate includes one or more fibers that are comprised of a polymer.3. The wound covering of claim 2 , wherein the polymer includes poly(ε-caprolactone) (PCL) claim 2 , poly(-lactide) (PLA) claim 2 , cellulose claim 2 , or combinations thereof.4. The wound covering of claim 1 , wherein the fiber is an electrospun fiber.5. The wound covering of claim 4 , wherein the electrospun fiber is plasma-treated.6. The wound covering of claim 1 , wherein the one or more fibers form a mesh.7. The wound covering of claim 1 , wherein the one or more fibers form a wound dressing.8. The wound covering of claim 1 , wherein the wound covering is biodegradable.9. The wound covering of claim 1 , wherein the wound covering is biocompatible.10. The wound covering of claim 1 , wherein the wound covering is configured to release the vitamin D claim 1 , or analogues or metabolites thereof claim 1 , under physiological conditions for at least about 1 day to about 50 days.11. The wound covering of claim 1 , further comprising a bioactive agent.12. The wound covering of claim 11 , wherein the bioactive agent is selected from antibiotics claim 11 ...

Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIES

Disclosed are solid and frozen haemostatic materials and dressing's consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings. 1. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 6% to 44%.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material has a plurality of particles , wherein said particles each have the same composition , and wherein the moisture content of said hemostatic material is from 1% to 6%.3. A method for treating wounded internal tissue in a mammal comprising applying to svounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is cast or formed as a single piece.4. The method of claim 1 , wherein said haemostatic material includes at least one support layer.5. The method of claim 4 , wherein said support layer comprises a backing material.6. The method of claim 4 ...

BIORESORBABLE WOUND DRESSING

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics. 1. A non-woven fabric comprising:fibres of a fibre raw material comprising bioresorbable and/or biocompatible polymers, the fibres including at least one biologically active substance, which is distributed in the fibres, wherein the biologically active substance is a GDF-5-related protein.2. The non-woven fabric of claim 1 , wherein the biologically active protein is additionally distributed on the fibres.3. The non-woven fabric of claim 1 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 60% to the 102 aa-cystine-knot-domain of human GDF-5 according to amino acids 400-501 of SEQ ID NO:2.4. The non-woven fabric of claim 3 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 70% claim 3 , 80% claim 3 , 90% or 95% to the 102 aa cystine-knot-domain of human GDF-5.5. The non-woven fabric of claim 1 , wherein the fibre raw material is selected from the group consisting of natural polymers claim 1 , synthetic polymers claim 1 , and polymers derived from fossile raw materials claim 1 , each of which may be modified or unmodified claim 1 , and combinations thereof.6. The non-woven fabric of claim 5 , wherein the natural polymers are selected from the group consisting of polypeptides such as collagen claim 5 , gelatin claim 5 , fibrin claim 5 , and casein claim 5 , polysaccharides such as dextran claim 5 , cellulose claim 5 , starch claim 5 , chitin claim 5 , chitosan claim 5 , alginate and hyaluronic acid claim 5 , polynucleotides claim 5 , and synthetic polymers such as polylactide (PLA) claim 5 , polyglycolide (PGA) ...

WOUND CARE COMPOSITIONS

Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (BO) intermixed into a carrier which is an ointment, cream, or surgical glue. 1. Glass-based particles of a biocompatible material intermixed into a carrier ,{'sub': 2', '3, 'wherein the glass-based particles comprise from 40 to about 80 wt % BO;'}wherein the carrier is a biocompatible ointment or cream or a surgical glue.2. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise one or more alkali oxides selected from the group consisting of LiO claim 1 , NaO claim 1 , KO claim 1 , and RbO claim 1 , and one or more alkaline earth oxides selected from the group consisting of MgO claim 1 , SrO claim 1 , BaO claim 1 , and CaO.3. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise from about 50 to about 80 wt % BO.4. The glass-based particles intermixed into a carrier of claim 1 , wherein the glass-based particles comprise from about 5 to about 20 wt % of one or more alkali oxides selected from the group consisting of LiO claim 1 , NaO claim 1 , KO claim 1 , and RbO claim 1 , and from about 5 to about 40 wt % of one or more alkaline earth oxides selected from the group consisting of MgO claim 1 , SrO claim 1 , BaO claim 1 , and CaO.5. The glass-based particles intermixed into a carrier of wherein the glass-based particles further comprise one or more trace elements selected from the group consisting of Ag claim 1 , Cu claim 1 , F claim 1 , Fe claim 1 , Mn claim 1 , Mo claim 1 , Ni claim 1 , Sr claim 1 , and Zn in a concentration between about 0.05 and 10 wt % per trace element chemically dissolved in glass.6. The glass-based particles intermixed into a carrier of wherein the glass-based particles further comprise one or more trace elements selected from the group consisting of Ag claim 4 , Cu claim 4 , F claim 4 , Fe claim 4 , Mn claim 4 , Mo claim 4 , Ni claim 4 , Sr ...

Hemostatic Pad Assembly Kit and Method

The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue. 1. A hemostatic wound treatment device comprising:a bioabsorbable scaffold having a wound facing surface and an opposing surface;said scaffold wetted with a biocompatible liquid that is not blood or plasma; anda hemostatic powder that adheres by moisture to at least the wound facing surface of said bioabsorbable scaffold.2. The hemostatic wound treatment device of wherein the hemostatic powder comprises a mixture of dry fibrinogen and dry thrombin.3. The hemostatic wound treatment device of wherein the hemostatic powder comprises dry fibrinogen.4. The hemostatic wound treatment device of wherein the hemostatic powder comprises dry thrombin.5. The hemostatic wound treatment device according to wherein the biocompatible liquid is selected from the group consisting of an aqueous solution claim 1 , normal saline claim 1 , ethanol claim 1 , and ethanol-water mixture.6. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises a hemostatic agent.7. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises thrombin claim 6 , fibrinogen claim 6 , hemostasis promoting agents claim 6 , growth factors claim 6 , calcium salts claim 6 , absorbable disaggregation aids claim 6 , bulking agents claim 6 , gelatin claim 6 , collagen claim 6 , and combinations thereof.8. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises proteins claim 7 , prothrombin claim 7 , fibrin claim 7 , fibronectin claim 7 , heparinase claim 7 , Factor X/Xa claim 7 , Factor VII/VIIa claim 7 , Factor IX/IXa claim 7 , Factor XI/XIa claim 7 , Factor XII/XIIa claim 7 , tissue factor ...

Composite material

According to embodiments, a composite material is disclosed. The composite material has a multi-layered structure, wherein the multi-layered structure is constituted by a hydrophilic biodegradable polymer and a collagen. In particular, the collagen is strip-shaped and has a fiber length from 1.5 mm to 50 mm. There are at least ten stacked layers per 5 μm of thickness in the multi-layered structure.

A NANOBIOCOMPOSITE FORMULATION FOR WOUND HEALING AND A PROCESS FOR THE PREPARATION THEREOF

The present invention involves the isolation of plant based CNCs from the leaves of . For the formation of NCs, a novel greener approach using LE as reducing agent for in situ impregnation of AgNPs as fillers into CNCs as matrix is reported. The silver nitrate solution in three different concentrations of 1 mM, 5 mM and 10 mM was used to form NCs where AgNPs have been incorporated into CNCs matrix. The CNCs and NCs were characterized using SEM, TEM, XRD, Zeta potential, FT-IR, and UV-Vis spectroscopy. NCs developed in the form of film and ointment showed strong antimicrobial activity against both gram negative and gram positive bacteria. NCs wound dressing is capable of regulating wound exudates and providing moisture to wound responsible for faster healing of acute wounds. The observations from histopathological and biochemical assays confirmed that NCs enhance healing because of lesser inflammation, rapid angiogenesis, early collagen formation and enhanced rate of reepithelization. 1Syzygium cumini. A nanobiocomposite formulation (NCs) in ointment form comprising silver nanoparticles (AgNPs) and cellulose nanocrystals (CNCs) wherein the ratio of AgNPs and CNCs is in the range of 0.067%-0.4% w/w AgNPs: 7-8% w/w CNCs , and wherein the cellulose is derived from leaves.2. A process for the preparation of the nanobiocomposite formulation in ointment form as claimed in claim 1 , the method comprising:{'i': 'Syzygium cumini', 'a) treating washed and dried leaves with bleaching agent at pH in the range of 3.0-4.0 for a time period ranging between 2-3 h at a temperature ranging between 70-100° C. to obtain a bleached fibrous material;'}b) filtering and washing the bleached fibrous material as obtained from (a) followed by treating with acidified bleaching agent solution at a temperature ranging between 22-30° C. for a time period ranging 16-18 h to obtain acidified fibrous material;c) washing the acidified fibrous material as obtained from (b) followed by keeping it into 2 ...

ENZYMATIC DEBRIDEMENT THERAPY FOR ABNORMAL CELL PROLIFERATION

Compositions and methods are provided to destroy internal cancerous lesions selectively by the administration of a combination of a debridement protease enzyme and a denaturant of cell structural proteins and or cell adhesion proteins. 1. A method for the treatment of a neoplasm , comprising administering to a patient in need thereof a treatment effective amount of a composition consisting essentially of one or more debridement enzyme and one or more denaturant , wherein the neoplasm is not a disorder of the skin.2. The method of wherein the debridement enzyme is selected from the group consisting of a plasma enzyme claim 1 , a pancreatic enzyme claim 1 , a cysteine protease claim 1 , a serine protease claim 1 , and a metallopeptidase.3. The method of wherein the debridement enzyme is selected from the group consisting of fibrinolysin claim 1 , desoxyribonuclease claim 1 , trypsin claim 1 , chymotrypsin claim 1 , krillase claim 1 , bromelain claim 1 , papain claim 1 , ficin claim 1 , subtilisins claim 1 , proteinase K claim 1 , collagenase claim 1 , vibriolysin claim 1 , thermolysin claim 1 , streptokinase and streptodomase.4. The method of wherein the debridement enzyme is papain.5. The method of wherein the debridement enzyme is administered in a dose in the range 1×10to 1×10USP per gram.6. The method of wherein the debridement enzyme is administered in a dose of about 1.1×10USP per gram.7. The method of wherein the denaturant is selected from the group consisting of urea claim 1 , lactic acid claim 1 , citric acid claim 1 , an aliphatic alcohol claim 1 , β-mercaptoethanol claim 1 , a detergent claim 1 , sodium dodecyl sulfate claim 1 , formaldehyde claim 1 , acetone claim 1 , acetonitrile claim 1 , dimethylsulfoxide claim 1 , dimethylformamide claim 1 , propylene carbonate claim 1 , ethylene carbonate; a metal scavenger; crown ethers; a crown amine; a polyether; polyethyleneoxide; a polyamine; polyethyleneamine; cryptands; ethylenediaminetetraacetic acid or its ...

OXYGEN-GENERATING COMPOSITIONS FOR ENHANCING CELL AND TISSUE SURVIVAL IN VIVO

A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer. 1. A method of treating hypoxic tissue in need thereof , comprising contacting a composition to said hypoxic tissue in a hypoxia-treatment effective amount , wherein said composition comprises a biodegradable polymer and an inorganic peroxide in solid form incorporated into said polymer , and wherein said hypoxic tissue is wound tissue , tissue afflicted with an anaerobic infection or cancer tissue.2. The method of claim 1 , wherein said hypoxic tissue is in vivo in a subject in need of said treatment.3. The method of claim 1 , wherein said tissue is wound tissue and said composition is administered in an amount effective to facilitate the healing of said wound tissue.4. The method of claim 2 , further comprising the step of concurrently treating said wound tissue with negative pressure wound therapy.5. The method of claim 1 , wherein said tissue is afflicted with an anaerobic infection and said composition is administered in an amount effective to treat said infection.6. The method of claim 1 , wherein said tissue is cancer tissue and said composition is administered in an amount effective to treat said cancer.7. The method of claim 1 , wherein said composition is in the form of a sheet material claim 1 , and said contacting step is carried out by contacting said sheet material to said tissue.8. The method of claim 1 , wherein said composition is in the form of injectable microparticles claim 1 , and said contacting step is carried out by injecting said microparticles into said tissue.9. The method of claim 1 , wherein said composition is in the form of a spray claim 1 , and said contacting step is carried out by spraying said composition onto said tissue.10. The method of claim 1 , wherein said composition ...

NEW WOUND DRESSING COMPOSITIONS

A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds. 1. A wound dressing composition comprising a non-viable cell lysate or releasate derived from an inflammatory cell.2. A wound dressing composition according to claim 1 , wherein the cell lysate or releasate is dispersed in or on a pharmaceutically acceptable vehicle.3. A wound dressing composition according to claim 2 , wherein said pharmaceutically acceptable vehicle is in the form of a solid sheet claim 2 , a semi-solid ointment claim 2 , an apertured solid sheet claim 2 , a web claim 2 , a woven fabric claim 2 , a knitted fabric claim 2 , a nonwoven fabric claim 2 , a hydrophilic foam claim 2 , a freeze-dried sponge or a solvent-dried sponge.4. A wound dressing composition according to claim 3 , wherein said pharmaceutically acceptable vehicle comprises a bioabsorbable freeze-dried sponge.5. A wound dressing composition according to claim 1 , wherein the cell releasate or lysate is dispersed in or on a solid vehicle that comprises claim 1 , or consists essentially of claim 1 , a solid bioabsorbable material selected from the group consisting of collagen claim 1 , chitosan claim 1 , oxidized cellulose claim 1 , or mixtures thereof.6. A wound dressing composition according to which is substantially dry.7. A wound dressing composition according to claim 1 , wherein the composition further comprises from about 0.01 to about 10% by weight on a dry weight basis of one or more wound healing therapeutic substances.8. A wound dressing composition according to which is substantially sterile.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. A process for the production of a wound dressing comprising the steps of lysing hepatocyte or ...

Hydrophilic medical devices

A medical device including a plasma-treated porous substrate that is functionalized to provide a hydrophilic surface, and a process for preparing such a medical device, are disclosed. The method includes plasma treating at least a portion of a surface of a porous substrate with a gas species selected from oxygen, nitrogen, argon, and combination thereof. The gas species is configured to functionalize the surface of the medical device and form a hydrophilic surface.

POLYMERIC MESH WITH SELECTIVE PERMEABILITY, FOR THE REPAIR AND REGENERATION OF TISSUES

The present application describes a polymeric mesh for the repair and regeneration of tissues from an organism that comprises pores wherein at least 70% of the pores of the said mesh have a size smaller than the one required to confine the cells of the said tissues, and wherein at least 70% of the pores of the said mesh has a size superior than the one needed for the passage of interstitial fluids of the said tissues; the degradation time of the said polymeric mesh within the organism is at least 8 weeks; the said polymeric mesh has an apparent tensile strength superior than 1 MPa; the said polymeric mesh has an apparent elastic modulus superior than 0.1 MPa. The mesh described in this application allows that the “new tissue” formed presents very similar properties to the ones of the damaged tissue. 125-. (canceled)26. A polymeric mesh for the repair and regeneration of tissues of an organism , the mesh comprising pores , wherein at least 70% of the pores of the mesh have a size smaller than required to confine the cells of the tissues , and wherein at least 70% of the pores of the mesh have a size larger than needed for the passage of interstitial fluids of the tissues ,wherein a degradation time of the mesh within the organism is at least 8 weeks and wherein the polymeric mesh comprises:an apparent tensile strength between 2.15-4.38 MPa,an apparent elastic modulus between 8.58-27.87 MPa, andan interconnected porosity ranging between 83-91% in which 80-90% of the pores have a size ranging between 1.2-13.37 μm.27. A polymeric mesh according to claim 26 , wherein the degradation time of the polymeric mesh is between about 8 and about 15 weeks.28. A polymeric mesh according to claim 26 , wherein the mesh comprises at least one synthetic polymer selected from polycaprolactone claim 26 , polyglycolic acid claim 26 , polylactic acid claim 26 , chitosan claim 26 , alginate or dextran claim 26 , or combinations thereof.29. A polymeric mesh according to claim 28 , further ...

Hydrogen Sulfide (H2S) Releasing Donor Compound For Dermal Wound Regeneration

A dressing for wound healing is provided, wherein the dressing includes a hydrogen sulfide (HS) donor compound. The dressing facilitates the delivery of HS to a wound site in a controlled manner, which results in an improved wound healing process by stimulating angiogenesis and anti-inflammatory action. In some embodiments, the wound dressing can include an electrospun nanofiber dressing, a sponge dressing, or a hydrogel dressing. 1. A wound dressing comprising:a biodegradable scaffold material; anda hydrogen sulfide donor, wherein the hydrogen sulfide donor is present in the wound dressing in an amount ranging from about 0.1 millimolar to about 150 millimolar.3. The wound dressing of claim 1 , wherein the wound dressing releases hydrogen sulfide when introduced into an environment having a pH ranging from 5.0 to 7.0.4. The wound dressing of claim 1 , wherein the wound dressing releases hydrogen sulfide for a time period of up to 75 hours.5. The wound dressing of claim 1 , wherein the wound dressing releases hydrogen sulfide at a concentration ranging from 5 micromolar (μM) to 50 μM.6. The wound dressing of claim 1 , wherein the biodegradable scaffold material comprises a biodegradable polymer claim 1 , sodium alginate claim 1 , hyaluronic acid claim 1 , or a combination thereof.7. The wound dressing of claim 6 , wherein the biodegradable polymer comprises polycaprolactone claim 6 , polylactic acid claim 6 , polyglycolic acid claim 6 , or a combination thereof.8. The wound dressing of claim 1 , wherein the biodegradable scaffold material comprises a nanofibrous scaffold claim 1 , a sponge claim 1 , or a hydrogel.9. The wound dressing of claim 8 , wherein the nanofibrous scaffold is an electrospun nanofibrous scaffold.10. The wound dressing of claim 1 , wherein the biodegradable scaffold material is crosslinked.11. The wound dressing of claim 1 , wherein wound dressing increases the production of CD31 and Ki67 from a wound.12. A method of treating a wound claim 1 , ...

BIODEGRADABLE MATERIAL AND METHOD OF PRODUCING BIODEGRADABLE MATERIAL

A biodegradable material is a chemically cross-linked product between a multivalent compound A having 3 or more functional groups X such as hydroxyl group; and a multivalent compound B having 3 or more functional groups Y such as carboxyl group wherein chemical cross-linkage(s) is/are formed by condensation reaction of the functional group(s) X and the functional group(s) Y; wherein (y+z)/(x+z) is 1.2 to 4.0 when MA>MB, and (x+z)/(y+z) is 1.2 to 4.0 when MA Подробнее

Sealant Dressing with Protected Reactive Components

The present invention is directed to multi-layered wound dressings having a carrier layer, at least two sublayers, wherein each sublayer contains at least one reactive, cross-linkable component and the at least two reactive, cross-linkable components are co-reactive with the other and at least one reactive, cross-linkable has a protective leaving group and a buffering salt agent.

BIODEGRADABLE MATERIAL AND METHOD OF PRODUCING BIODEGRADABLE MATERIAL

A biodegradable material has an improved biodegradability, an enhanced shape recovery rate after deformation of the material and an improved flexibility. The biodegradable material is a chemically cross-linked product of: a multivalent compound A having 3 or more functional groups X such as hydroxyl group; a multivalent compound B having 3 or more functional groups Y such as carboxyl group; and a compound C having a structure originated from a hydroxycarboxylic acid whose homopolymer formed by homopolymerization has a glass transition point of −40° C. or lower. 116-. (canceled)17. A biodegradable material which is a chemically cross-linked product of:a multivalent compound A having 3 or more functional groups X selected from the group consisting of hydroxyl group, thiol group and amino group;a multivalent compound B having 3 or more functional groups Y selected from the group consisting of carboxyl group, isocyanate group and thioisocyanate group; anda compound C having a structure originated from a hydroxycarboxylic acid whose homopolymer formed by homopolymerization has a glass transition point of −40° C. or lower.18. The biodegradable material according to claim 17 , wherein the weight ratio of said structure originated from said compound C is 18 to 70% by weight.19. The biodegradable material according to claim 17 , wherein said multivalent compound A is one of a) to e):a) a homopolymer or a copolymer of a monomer(s) of a water-soluble polymer(s) selected from the group consisting of polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate, carboxymethyl cellulose, hydroxymethyl cellulose and hydroxyethyl cellulose;b) a copolymer of the monomer of said water-soluble polymer and a monomer(s) of a hydrophobic polymer(s) selected from the group consisting of vinyl acetate and vinyl caprolactam;c) a copolymer of the monomer of said water-soluble polymer and a hydroxycarboxylic acid(s) whose homopolymer(s) ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

HYDROGELS WITH BIODEGRADABLE CROSSLINKING

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. 1. A method to prepare a drug-releasing degradable hydrogel , which method comprises(a) providing a first multi-armed polymer wherein each arm is terminated by a group comprising orthogonal first and second functional groups, which first orthogonal functional group is different from said second orthogonal functional group;(b) reacting said first multi-armed polymer of (a) with a linker-drug conjugate wherein said conjugate comprises a third functional group that reacts with only the first orthogonal functional group to obtain a derivatized first polymer; and(c) reacting the derivatized first polymer obtained in (b) with a crosslinker coupled to a second multi-armed polymer wherein said crosslinker comprises a fourth functional group that reacts with only the second orthogonal functional group present on said derivatized polymer to obtain said drug-releasing degradable hydrogel, or(d) reacting said first multi-armed polymer of (a) with a crosslinker coupled to a second multi-armed polymer wherein said crosslinker comprises a fourth functional group that reacts only with the second orthogonal functional group to obtain a crosslinked polymer, and(e) reacting the crosslinked polymer of (d) with a linker-drug conjugate, wherein said conjugate comprises a third functional group that reacts with only the first orthogonal functional group to obtain a said drug-releasing degradable hydrogel.2. The method of wherein the linker-drug conjugate is degradable by a beta elimination reaction.4. The method of wherein the crosslinker is degradable by a beta elimination reaction.6. The method of wherein the linker-drug conjugate is of Formula (3).7. The method of wherein each said functional group independently comprises N claim 1 , NH ...

SYNTHESIS OF HYPERBRANCHED POLYMETHACRYLATES AND POLYACRYLATES BY A HALOINIMER APPROACH

A new synthetic pathway for hyperbranched polyacrylates and polymethacrylates including the steps of preparing an inimer and polymerizing the inimer to form hyperbranched polymers or copolymers. 1. A method for preparing hyperbranched polyacrylates or polymethacrylates , the method comprising:(a) reacting a halohydrin containing a carboxylic acid group with an anhydride in the presence of an acid catalyst, to form a pre-inimer that contains a carboxylic acid group;(b) reacting the pre-inimer with a chlorinating agent to form an acid chloride;(c) reacting the acid chloride with an alcohol in the presence of trimethylamine to esterify the acid chloride and form an inimer; and(d) polymerizing the inimer to form a hyperbranched polyacrylate or polymethacrylate polymer by self-condensing vinyl polymerization, or copolymerizing the inimer with one or more monomers using self-condensing vinyl co-polymerization.9. The method of claim 1 , wherein the method further comprises the step of stabilizing a protein by using the hyperbranched polyacrylate or polymethacrylate polymer or a copolymer thereof.10. The method of claim 1 , wherein the method further comprises the step of protein capture by using the hyperbranched polyacrylate or polymethacrylate polymer or a copolymer thereof.11. A method for preparing hyperbranched polyacrylates or polymethacrylates claim 1 , the method comprising:(a) reacting a halohydrin containing a carboxylic acid group with an anhydride in the presence of an acid catalyst, to form a pre-inimer that contains a carboxylic acid group;(b) reacting the pre-inimer with an alcohol using carbodiimide coupling or a Mitsunobu reaction to form an ester inimer; and(c) polymerizing the inimer to form a hyperbranched polyacrylate or polymethacrylate polymer by self-condensing vinyl polymerization, or copolymerizing the inimer with one or more monomers using self-condensing vinyl co-polymerization.17. The method of claim 11 , wherein the method further comprises ...

BIORESORBABLE WOUND DRESSING

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics. 116.-. (canceled)17. A non-woven fabric comprising:fibres of a fibre raw material comprising bioresorbable and/or biocompatible polymers, the fibres including at least one biologically active substance, which is distributed in the fibres, wherein the biologically active substance is a GDF-5-related protein.18. The non-woven fabric of claim 17 , wherein the biologically active protein is additionally distributed on the fibres.19. The non-woven fabric of claim 17 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 60% to the 102 aa-cystine-knot-domain of human GDF-5 according to amino acids 400-501 of SEQ ID NO:2.20. The non-woven fabric of claim 19 , wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 70% claim 19 , 80% claim 19 , 90% or 95% to the 102 aa cystine-knot-domain of human GDF-5.21. The non-woven fabric of claim 17 , wherein the fibre raw material is selected from the group consisting of natural polymers claim 17 , synthetic polymers claim 17 , and polymers derived from fossile raw materials claim 17 , each of which may be modified or unmodified claim 17 , and combinations thereof.22. The non-woven fabric of claim 21 , wherein the natural polymers are selected from the group consisting of polypeptides such as collagen claim 21 , gelatin claim 21 , fibrin claim 21 , and casein claim 21 , polysaccharides such as dextran claim 21 , cellulose claim 21 , starch claim 21 , chitin claim 21 , chitosan claim 21 , alginate and hyaluronic acid claim 21 , polynucleotides claim 21 , and synthetic polymers such as ...

TISSUE PATCH

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. For example, in some embodiments, tissue patches are made by applying a compressive force to a liquid medium comprising fibrinogen (and/or fibrin) between two surfaces (e.g., within a syringe or other chamber). A filter can be placed within or near the volume in which the compressive force is applied to the liquid medium such that unwanted material (e.g., water, blood cells, and the like) is passed through the filter while desirable components (e.g., fibrin, fibrinogen, and/or other desirable components) are retained by the filter to form the patch. In this way, the concentration of fibrin (and/or fibrinogen) within the liquid medium can be increased, potentially dramatically, as the compressive force is applied to the liquid-containing composition. In addition, in some embodiments, at least a portion of the fibrinogen and/or fibrin can chemically react (e.g., the fibrinogen can polymerize to form fibrin and/or the fibrin can cross-link) during application of the compressive force. Reaction and concentration can lead to the formation of a highly-concentrated, mechanically robust patch that can be handled relatively easily and provide good structural reinforcement at a wet site, such as a bleeding wound. 1. (canceled)2. A patch , comprising:a primer region comprising a water-activated polymeric adhesive; anda solid matrix positioned over at least a portion of the primer region, the water-activated polymeric adhesive comprises one or more polymers of acrylic acid cross-linked with a polyalkenyl ether and/or a divinyl alcohol; and', 'the patch is configured for application to a tissue surface., 'wherein3. The patch of claim 2 , wherein the solid matrix comprises fibrin.4. The patch of claim 2 , wherein the solid ...

DRESSING FOR COMPROMISED WOUND HEALING

The invention relates to a bioactive medical product, or dressing, characterised in that it comprises at least an inner layer formed by a hydrogel and an outer layer formed by a biodegradable and bioabsorbable polyurethane, said inner layer being impregnated with an N-terminal peptide of 20 amino acids of pro-adrenomedullin and the outer layer being impregnated with nanoparticles of bemiparin encapsulated in a biodegradable copolymer or polymer. The active components can be dosed in a sequential and controlled manner with this composition. The invention also relates to a method for producing the two-layer dressing and to the use thereof in medicine, said dressing being specially designed to treat and promote the healing of wounds, such as compromised wounds and ulcers, particularly in patients with diabetes and reduced blood supply. 2. The dressing according to claim 1 , wherein the crosslinking agent is selected from the group consisting of genipin claim 1 , sodium tripolyphosphate claim 1 , sodium glycerol phosphate and salicin.3. The dressing according to claim 2 , wherein the crosslinking agent is genipin.4. The dressing according to claim 1 , wherein the crosslinking agent is contained in the hydrogel in a concentration comprised between 0.5% and 10% by weight with respect to the polymer mixture claim 1 , including both limits.5. The dressing according to claim 1 , wherein the hydrogel consists of 60% by weight of gelatin and 40% by weight of sodium hyaluronate over the polymeric mass of the hydrogel.6. The dressing according to claim 1 , wherein the hydrogel additionally comprises at least one polymer selected from collagen claim 1 , chitosan and dextran.7. The dressing according to claim 1 , wherein the polyurethane has a molecular weight comprised between 3000 and 40000 Daltons claim 1 , including both limits.8. The dressing according to claim 7 , wherein the polyurethane consists of a soft segment ABformed from polycaprolactone diol and pluronic 61 claim 7 ...

COLLAGEN-CONTAINING WOUND DRESSING AND METHOD FOR THE PRODUCTION THEREOF

The invention relates to a method for producing an implant, which is in particular in the form of a wound dressing. The implant consists of a sheet-like structure made of magnesium, which is embedded in a collagen non-woven fabric. 115-. (canceled)16. A method for producing a geometrically stable bioresorbable wound dressing membrane , the method comprising:covering a sheet-like structure made of magnesium or a magnesium alloy with a collagen-containing preparation; anddrying of the collagen-containing preparation.17. The method for producing the wound dressing membrane of claim 16 , wherein the collagen-containing preparation comprises a collagen-containing suspension.18. The method for producing the wound dressing membrane of claim 17 , wherein the suspension includes a native collagen.19. The method for producing the wound dressing membrane of claim 16 , wherein the sheet-like structure comprises a mesh.20. The method for producing the wound dressing membrane of claim 16 , further comprising applying the sheet-like structure onto a support.21. The method for producing the wound dressing membrane of claim 20 , wherein the support comprises a collagen membrane.22. The method for producing the wound dressing membrane of claim 16 , further comprising adjusting the collagen-containing preparation to a pH value of greater than 5.5 claim 16 , at least prior to the covering the sheet-like structure with the collagen-containing preparation.23. The method for producing the wound dressing membrane of claim 16 , wherein the drying of the collagen-containing preparation is performed by lyophilization.24. The method for producing the implant of claim 21 , wherein the support comprises a lyophilized skin of animal or a human origin collagen.25. A wound dressing comprising:a collagen-containing sheet-like structure; anda sheet-like structure made of magnesium or a magnesium alloy, comprising openings, the sheet-like structure made of the magnesium or the magnesium alloy embedded ...

Biomedical Foams

The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides an absorbent foam, suitable for packing antrums or other cavities of the human or animal body, comprising a biodegradable synthetic polymer, which polymer preferably comprises —C(O)—O— groups in the backbone of the polymer, for instance polyurethane and/or polyester units combined with polyethers. 1. A method of preparing a foam suitable for packing antrums or other cavities of the human or animal body , said method comprising the steps of: [{'br': None, 'A-R-A′\u2003\u2003(III),'}, {'br': None, 'O═C═N—R′—N═C═O \u2003\u2003(IV),'}, 'with one or more diisocyanates of a formula (IV), [{'br': None, 'B—R″—B′\u2003\u2003(V),'}, 'wherein A, A′, B and B′ are independently selected from hydroxyl, carboxyl or amine,', 'wherein R is selected from one or more aliphatic polyesters, polyetheresters, polyethers, polyanhydrides and/or polycarbonates, and at least one R comprises an amorphous segment and a crystalline segment, wherein the amorphous segment comprises a hydrophilic segment comprising polyethyleneglycol, polypropyleneglycol or polybutyleneglycol, and', {'sub': 2', '8', '1', '10', '1', '10', '2', '8, 'wherein R′ and R″ are independently C-Calkylene, optionally substituted with C-Calkyl or C-Calkyl groups substituted with protected S, N, P or O moieties and/or comprising S, N, P or O in the C-Calkylene;'}], 'and one or more chain extenders of a formula (V)], 'producing a phase-separated polymer in a solvent by reacting one or more pre-polymers according to a formula (III)cooling the phase-separated polymer in the solvent to crystallize the polymer and crystallize the ...

BILAYERED DEVICES FOR ENHANCED HEALING

Disclosed herein is a multilayered wound dressing comprising a first layer; the first layer including channels that facilitate neovascularization of a wound; and a second layer in contact with the first layer, the second layer having the same or different chemical composition as the first layer; where the second layer comprises at least one surface that has a texture and the direction of the texture is operative to facilitate cell orientation and growth. A method includes forming a first layer of a polymeric material; forming a second layer of the same polymeric material as the first layer on the first layer; and forming a textured surface of the second layer of the same polymeric material as the first layer, the textured surface being operative to facilitate directional cell growth when used in a wound dressing, where the first layer and the second layer are formed using an additive manufacturing process. 157-. (canceled)58. A multilayered wound dressing comprising:a first layer; the first layer comprising channels that facilitate neovascularization of a wound; anda second layer in contact with the first layer, the second layer having the same or different chemical composition as the first layer; wherein the second layer comprises at least one surface that has a texture that comprises a plurality of spaced features; wherein each feature has a substantially different geometry than a neighboring feature; the plurality of spaced features arranged in a plurality of groupings, the spaced features within each of the groupings being spaced apart at an average distance of about 10 nanometers to about 200 micrometers; the adjacent groupings of features being spaced from each other to define an intermediate tortuous pathway.59. The multilayer wound dressing of claim 58 , wherein the first layer comprises a surface that has a texture that is complementary to a patient's anatomy where the wound is located.60. The multilayer wound dressing of claim 58 , wherein the first layer ...

Film

Disclosed is a film which is able to suppress agglutination by being continuously adhered to an adhesion target portion in a biological body while suppressing a position shift. A film includes an adhesive and an adhesion inhibiting layer. The adhesive layer absorbs and maintains a liquid in a plurality of pores which are opened in one film surface and has a capillary force for adhering the adhesive layer to a first-cell group. The adhesive layer is formed of a biodegradable polymer. The adhesion inhibiting layer configures the other film surface, and inhibits adhesion between a second-cell group which is different from the first-cell group and the adhesive layer. In the adhesive layer, the pore is formed not to be penetrated in a thickness direction of the film, and thus the first-cell group and the second-cell group are separated into the one film surface side and the other film surface side.

DRUG-ELUTING MEDICAL DEVICES

Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures. 1. A composite structure comprising a device and at least one polymeric porous coat coating at least a part of said device and encapsulating at least one bioactive agent , said coat being capable of encapsulating said at least one bioactive agent while retaining an activity of said bioactive agent and/or capable of releasing said bioactive agent in a pre-determined release rate , with the proviso that said device is not a fiber and further with the proviso that when said device is comprised of fibrous elements , said coat is not coating said fibrous elements at the contact point of intercrossing junctions of said fibrous elements in said device , such that said fibrous elements are in contact with each other in each of said junctions.2. The composite structure of claim 1 , wherein said device is a medical device.3. The composite structure of claim 2 , wherein said device is a medical device selected from the group consisting of a mesh claim 2 , a suture mesh claim 2 , a wound dressing claim 2 , a stent claim 2 , a skin patch claim 2 , a bandage claim 2 , a suture anchor claim 2 , a screw claim 2 , a pin claim 2 , a tack claim 2 , a rod claim 2 , an angioplastic plug claim 2 , a plate claim 2 , a clip claim 2 , a ring claim 2 , a needle claim 2 , a tube claim 2 , a dental implant claim 2 , an orthopedic implant claim 2 , a guided tissue matrix claim 2 , an aortic aneurysm graft device claim 2 , an atrioventricular shunt claim 2 , a catheter claim 2 , a heart valve claim 2 , a hemodialysis catheter claim 2 , a bone-fracture healing device claim 2 , a bone replacement device claim 2 , a joint replacement device claim 2 , a tissue regeneration device claim 2 , a ...

ANTIMICROBIAL DRESSING, DRESSING COMPONENTS, AND METHODS

A dressing that includes an absorbent, antimicrobial layer and a bioresorbable layer is disclosed herein. The absorbent, antimicrobial layer may be formed from nonwoven fibers. The bioresorbable layer may include an extracellular polymeric substance-active agent, such as citric acid. At least a portion of the nonwoven fibers may include carboxymethylcellulose fibers and alginate fibers. 1. A dressing comprisingan absorbent, antimicrobial layer comprising absorbent fibers and antimicrobial fibers; anda bioresorbable layer comprising a bioresorbable material and an extracellular polymeric substance (EPS)-active agent.2. The dressing of claim 1 , wherein the absorbent fibers comprise alginate fibers.3. The dressing of claim 1 , wherein the absorbent fibers comprise carboxymethylcellulose.4. The dressing of claim 1 , wherein the antimicrobial fibers comprise nylon fibers having an antimicrobial coating.5. The dressing of claim 4 , wherein the antimicrobial coating comprises silver.6. The dressing of claim 1 , wherein the absorbent fibers comprise a cellulosic material.7. The dressing of claim 1 , wherein the absorbent fibers comprise carboxymethylcellulose fibers and alginate fibers.8. The dressing of claim 1 , wherein the absorbent fibers comprise cellulose ethyl sulphonate fibers.9. The dressing of claim 1 , wherein the EPS-active agent comprises citric acid.10. The dressing of claim 1 , wherein the EPS-active agent comprises citric acid claim 1 , and wherein the bioresorbable layer comprises from 0.1% to 5% citric acid by weight to the bioresorbable layer.11. The dressing of claim 1 , wherein the bioresorbable material comprises gelatin claim 1 , collagen claim 1 , oxidized regenerated cellulose (ORC) claim 1 , or a combination of any two or more thereof.12. The dressing of claim 1 , wherein the bioresorbable material comprises collagen and oxidized regenerated cellulose (ORC) claim 1 , where a weight ratio of collagen to ORC in the bioresorbable layer is about 60:40 ...

BIOABSORBABLE SHEET OR FILM

The present invention relates to a bioabsorbable sheet or film, composed of a composition containing phosphorylated pullulan. The bioabsorbable sheet or film of the present invention can be suitably used in the medical fields, for example, as medical adhesives to be patched to a biotissue such as organs and blood vessels during surgical operations. 1. A bioabsorbable sheet or film , comprising a composition comprising phosphorylated pullulan.2. The sheet or film according to claim 1 , wherein the composition further comprises a plasticizer.3. The sheet or film according to claim 2 , wherein the plasticizer comprises at least one member selected from glycerol and polyethylene glycol.4. The sheet or film according to claim 1 , wherein the composition further comprises a bioactive agent.5. The sheet or film according to claim 1 , which is supported by a supporting sheet.6. The sheet or film according to claim 1 , which is a coating agent for a wound site claim 1 , a defective site claim 1 , or a vulnerable site in an organ or tissue in a live body.7. The sheet or film according to claim 1 , which is a leakage or diffusion preventing material or a fixing material for regeneration or reconstruction of a tissue in a live body.8. The sheet or film according to claim 1 , which is a leakage or diffusion preventing material of a bioactive agent.9. A bioabsorbable sheet or film claim 1 , comprising a composition comprising a chemically modified phosphorylated pullulan.10. The sheet or film according to claim 9 , wherein the chemical modification is a chemical modification using a compound selected from the group consisting of etherification agents claim 9 , esterification agents claim 9 , acetal formation agents claim 9 , isocyanates claim 9 , isothiocyanates claim 9 , carbamoyl chloride claim 9 , thiocarbamoyl chloride claim 9 , silane coupling agents claim 9 , sulfonyl chlorides claim 9 , sulfonic acid anhydrides claim 9 , polymers claim 9 , and crosslinking agents for ...

READY TO USE BIODEGRADABLE AND BIOCOMPATIBLE DEVICE AND A METHOD OF PREPARATION THEREOF

A method is for making a hemostat device. The method includes preparing a homogenous solution of gelatin and chitosan by adding gelatin to water to form a gelatin solution, adding an acid to the gelatin solution to provide an acidified gelatin solution, and adding chitosan to the acidified gelatin solution to form the homogenous solution of gelatin and chitosan. The method also may include air drying the homogenous solution of gelatin and chitosan to provide an air dried scaffold, processing the air dried scaffold to provide a porous sponge, loading the porous sponge with a clotting agent by exposing the porous sponge to the clotting agent in an aqueous solution, and drying the loaded porous sponge. 1. A method for making a hemostat device , the method comprising: adding gelatin to water to form a gelatin solution,', 'adding an acid to the gelatin solution to provide an acidified gelatin solution, and', 'adding chitosan to the acidified gelatin solution to form the homogenous solution of gelatin and chitosan;, 'preparing a homogenous solution of gelatin and chitosan by at least'}air drying the homogenous solution of gelatin and chitosan to provide an air dried scaffold;processing the air dried scaffold to provide a porous sponge;loading the porous sponge with a clotting agent by exposing the porous sponge to the clotting agent in an aqueous solution; anddrying the loaded porous sponge.2. The method of wherein the loading comprises lyophilizing the porous sponge with the aqueous solution.3. The method of wherein the processing comprises cutting and crushing the air dried scaffold.4. The method of wherein the processing comprises stabilizing the air dried scaffold.5. The method of wherein the stabilizing comprises using one of ammonia vapor claim 4 , ammonia solution claim 4 , or alkali solution.6. The method of further comprising washing the porous sponge with water.7. The method of further comprising performing a physico-chemical treatment of the homogenous solution ...

Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds

According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.

METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIES

Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings. 1. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is substantially homogeneous.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator.3. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to join or approximate said wounded tissue and/or to reduce the flow of fluid from said wounded tissue , wherein said haemostatic material is cast or formed as a single piece.4. The method of claim 3 , wherein said haemostatic material includes at least one support layer.5. The method of claim 4 , wherein said support layer comprises a backing material.6. The method of claim 4 , wherein said support layer comprises an internal support material.7. The method of claim 4 , wherein said support layer comprises a resorbable material.8. The method of claim 4 , wherein ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE AND PROCESSES FOR MIXING FIBRINOGEN AND THROMBIN WHILE PRESERVING FIBRIN-FORMING ABILITY, COMPOSITIONS PRODUCED BY THESE PROCESSES, AND THE USE THEREOF

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal , said solid dressing comprising at least one haemostatic layer having a wound facing surface and an opposite surface , and consisting essentially of fibrinogen and a solvent consisting of water and a fibrinogen activator , wherein said haemostatic layer is substantially homogenous , and wherein said fibrinogen is present in an amount about 13.0 mg/cmof the wound facing surface of said dressing , and wherein the moisture content of said solid dressing is from 6% to 44%.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin cross-linker and/or a source of calcium ions.5. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.6. The solid dressing of claim 1 , wherein said haemostatic layer is cast as a single piece.7. The solid dressing of claim 1 , wherein said haemostatic layer is composed of a plurality of particles claim 1 , each of said particles consisting essentially of fibrinogen and thrombin.8. The solid dressing of claim 7 , wherein said haemostatic layer further contains at least one binding agent in an ...

NON-SURGICAL, LOCALIZED DELIVERY OF COMPOSITIONS FOR PLACENTAL GROWTH FACTORS

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery. 110-. (canceled)11. A composition comprising a sufficient amount of placental growth factors to treat a diseased or injured organ or body part wherein said composition is in the form of a localized mass when applied to or proximate to said diseased or injured organ or body part; wherein said composition is free of modified placental tissue particles; wherein said growth factors are extracted from modified placental tissue; and wherein said modified placental tissue comprises chorion.12. The composition of claim 11 , further comprising a localization agent.13. The composition of claim 12 , wherein the localization agent is a thixotropic agent claim 12 , or a phase changing agent.14. The composition of claim 13 , wherein the thixotropic agent is selected from the group consisting of hyaluronic acid claim 13 , collagen claim 13 , thrombin gels claim 13 , fibrin gels and fibrin glues.15. The composition of claim 13 , wherein the phase changing agent is a gel forming agent.16. The composition of claim 15 , wherein the gel forming agent is a copolymer or tripolymer of oxyethylene and oxypropylene units.17. The composition of claim 12 , wherein the localization agent is selected from the group consisting of a hydrogel claim 12 , a polymer claim 12 , and a collagen gel.18. A method for preparing a composition for localized delivery of placental growth factors claim 12 , comprising combining an aqueous solution of placental growth factors with a sufficient amount of a localization agent claim 12 , whereby the composition is locally retained at the site of delivery upon administration; wherein said composition is free of modified placental tissue particles; ...

HEMOSTATIC SPONGE

The present invention provides a hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing, particulate material adhered to said matrix material, a method of producing these sponges and their use for wound healing. 1. A hemostatic porous sponge comprising a matrix of a fibrous biomaterial and particles of a fluid absorbing particulate material adhered to said matrix material.2. The sponge according to claim 1 , wherein said fibrous biomaterial comprises collagen.3. The sponge according to claim 1 , wherein said particulate material is a hemostatic material.4. The sponge according to claim 3 , wherein said particulate material is a cross-linked polymer.5. The sponge according to claim 3 , wherein said particulate material comprises gelatin claim 3 , fibrin claim 3 , collagen or any mixture thereof.6. The sponge according to further comprising thrombin or a precursor of thrombin.7. The sponge according to further comprising an adhesive layer.8. The sponge according to claim 7 , wherein said adhesive layer comprises a bioresorbable polymer.9. The sponge according to claim 7 , wherein the adhesive comprises a first cross-linkable component claim 7 , a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions.10. The sponge according to claim 9 , wherein said first and/or second cross-linkable component comprise PEG or a derivative thereof.11. The sponge according to claim 7 , wherein said adhesive comprises succinimidyl or maleimidyl and thiol or amino groups.12. The sponge according to claim 7 , wherein said adhesive layer is discontinuously coated on at least one side of the sponge.13. The sponge according to being freeze-dried or air-dried.14. The sponge according to comprising a supporting layer with greater tensile strength than the matrix material.15. The sponge according to claim 14 , wherein said supporting layer comprises a bioresorbable polymer.16. ...

METHOD OF SEALING A DUROTOMY

A method of sealing a durotomy from which cerebrospinal fluid is leaking. A durotomy sealant dressing is prepared by applying an active agent to a dextran base. The durotomy sealant dressing is applied to a durotomy. At least a portion of the durotomy sealant dressing dissolves. The durotomy is sealed with the dissolved durotomy sealant dressing to substantially prevent cerebrospinal fluid from flowing through the durotomy. 1. A method of sealing a durotomy from which cerebrospinal fluid is leaking , wherein the method comprises:preparing a durotomy sealant dressing by applying an active agent to a dextran base;applying the durotomy sealant dressing to a durotomy;dissolving at least a portion of the durotomy sealant dressing; andsealing the durotomy with the dissolved durotomy sealant dressing to substantially prevent cerebrospinal fluid from flowing through the durotomy.2. The method of claim 1 , and further comprising applying pressure to the durotomy sealant dressing using a pledget when the durotomy sealant dressing is applied to the durotomy.3. The method of claim 1 , wherein the durotomy sealant dressing substantially dissolves in less than about 4 minutes when the durotomy sealant dressing is applied to the durotomy.4. The method of claim 1 , wherein the dextran base is fabricated from electrospun dextran fibers and wherein the active agent comprises at least one of thrombin and fibrinogen.5. The method of claim 1 , wherein preparing the durotomy sealant dressing comprises:forming at least two layers that each comprise the active agent applied to the dextran base; andplacing the layers adjacent to each other to form the durotomy sealant dressing.6. The method of claim 1 , and further comprising applying a liquid to the durotomy sealant dressing while the durotomy sealant dressing is applied to the durotomy.7. The method of claim 1 , and further comprising at least partially immersing the durotomy sealant dressing in a liquid before the durotomy sealant ...

Tissue derived porous matrices and methods for making and using same

Tissue derived porous matrices for treating wounds are provided, as well as methods for making and using them. The tissue derived porous matrices comprise processed tissue of any of several types, such as dermis, adipose, etc., and have a plurality of interconnected pores which allow fluid flow through the matrices. The tissue derived matrices are biocompatible resorbable matrices which remodel with native tissue and facilitate and enhance cell infiltration and tissue ingrowth into the matrices during the wound healing process, thereby enhancing wound healing and tissue remodeling when implanted into a patient. The tissue derived matrices are useful with reduced or negative pressure wound healing methods and systems, without the need to repeatedly revisit the treatment site and remove previously implanted matrices.

ABSORBENT ARTICLE HAVING NATURAL FIBERS

Herein is disclosed a biodegradable absorbent article having a natural fiber cake which may include a mixture of plant fibers and plant pulp, such as from a banana plant, and in embodiments, includes an absorbent article having a permeable top sheet; a natural fiber cake that may be derived from plant material such as the banana plant; a water-insoluble back sheet; and an optional superabsorbent polymer, and wherein the absorbent article may be used for many purposes such as a sanitary napkin or urinary incontinence pads. 1. A biodegradable and corn postable absorbent article , comprising:a natural fiber cake comprising a cellulosic material which comprises a mixture of velutinous plant pulp and cellulosic fibers.2. The absorbent article of claim 1 , wherein said cellulosic material is derived from banana fibers.3. The absorbent article of claim 1 , wherein said natural fiber cake in said absorbent article has an absorbency of from about 2 to about 14 g/g.4. An absorbent article claim 1 , comprising:a natural fiber cake comprising a cellulosic material which comprises from about 60 to about 99 weight percent of plant pulp and from about 1 to about 40 weight percent of plant fibers having a length of from about 20 mm to about 100 mm.5. The absorbent article of claim 4 , wherein said article is biodegradable.6. The absorbent article of claim 5 , wherein said plant pulp and plant fibers are derived from at least one plant selected from the group consisting of corn claim 5 , abaca claim 5 , wheat claim 5 , barley claim 5 , rice claim 5 , hemp claim 5 , sorghum claim 5 , sugarcane claim 5 , pineapple claim 5 , kenaf claim 5 , sisal claim 5 , jute claim 5 , banana claim 5 , tea leaves claim 5 , and combinations thereof.7. The absorbent material of claim 4 , wherein said cellulosic material comprises from about 70 to about 90 percent of velutinous banana pulp.8. The absorbent article of claim 4 , wherein said cellulosic material comprises from about 10 to about 30 weight ...

NOVEL HEMOSTATIC PATCH AND USES THEREOF

Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch. 19.-. (canceled)10. A hemostatic patch , wherein the patch comprises a mucoadhesive and a formulation of vasoconstrictant nanoparticles , wherein the vasoconstrictant nanoparticle comprises a vasoconstrictor selected from , Neuropeptide Y , Neuropeptide Y analogues , epinephrine , norepinephrine , vasopressin , phenylephrine , pseudoephedrine , metaraminol , Peptide YY , Angiotensin II , Muscarinic agonists , Endothelin; and , Andrenergic agonists , wherein the vasoconstrictor is encapsulated or immobilized on a bioabsorbable polymer.11. The hemostatic patch of claim 10 , wherein the bioabsorbable polymer comprises chitosan.12. The hemostatic patch of claim 10 , wherein the polymer comprises poly(lactic-co-glycolic acid) (PLGA).13. The hemostatic patch of claim 10 , wherein the polymer comprises chitosan crosslinked using glutaraldehyde.14. The hemostatic patch of claim 10 , wherein the polymer comprises chitosan crosslinked to PLGA.15. The hemostatic patch of claim 10 , wherein the vasoconstrictant nanoparticle comprises a vasoconstrictor selected from claim 10 , Neuropeptide Y claim 10 , Neuropeptide Y analogues claim 10 , epinephrine claim 10 , norepinephrine claim 10 , vasopressin claim 10 , phenylephrine claim 10 , pseudoephedrine claim 10 , metaraminol claim 10 , Peptide YY claim 10 , Angiotensin II claim 10 , Muscarinic agonists claim 10 , Endothelin; and/or claim 10 , Andrenergic agonists) claim 10 , and the vasoconstrictor is covalently bound to the polymer.16. (canceled)17. The hemostatic patch of claim 11 , wherein the chitosan ...

BIOADHESIVE COMPOSITION COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF

The present disclosure relates to a bioadhesive composition including mussel adhesive protein; and at least one of polyacrylic acid and polymethacrylic acid; in which the mussel adhesive protein is linked to the at least one of polyacrylic acid and polymethacrylic acid by an amide bond and has a three-dimensional network structure and a method for preparing the same. 1. A bioadhesive composition comprising mussel adhesive protein; and at least one of polyacrylic acid and polymethacrylic acid;wherein the mussel adhesive protein is linked to the at least one of polyacrylic acid and polymethacrylic acid by an amide bond, andwherein the bioadhesive composition has a three-dimensional network structure.2. The bioadhesive composition of claim 1 , wherein the mussel adhesive protein includes at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1 claim 1 , SEQ ID NO: 2 claim 1 , SEQ ID NO: 3 claim 1 , SEQ ID NO: 4 claim 1 , SEQ ID NO: 5 claim 1 , SEQ ID NO: 6 claim 1 , SEQ ID NO: 7 claim 1 , SEQ ID NO: 8 claim 1 , SEQ ID NO: 9 claim 1 , SEQ ID NO: 10 claim 1 , SEQ ID NO: 11 claim 1 , SEQ ID NO: 12 claim 1 , SEQ ID NO: 13 claim 1 , SEQ ID NO: 14 and SEQ ID NO: 15.3. The bioadhesive composition of claim 1 , wherein the mussel adhesive protein includes a catechol compound into which a tyrosine residue is converted; a catechol derivative introduced onto the surface of the mussel adhesive protein; or all of them.4. The bioadhesive composition of claim 3 , wherein the catechol compound includes at least one selected from the group consisting of DOPA (3 claim 3 ,4-dihydroxyphenylalanine) claim 3 , Dopa o-quinone claim 3 , TOPA (2 claim 3 ,4 claim 3 ,5-trihydroxyphenylalanine) claim 3 , Topa quinone and a derivative thereof.5. The bioadhesive composition of claim 1 , wherein the bioadhesive composition includes:a first component in which the mussel adhesive protein and polyacrylic acid are amide-bonded;a second component in which the mussel adhesive ...

FOAM COMPOSITIONS, FOAM MATRICES AND METHODS

Disclosed herein are matrices, compositions and methods of making matrices. The matrix comprises a biomolecule and the matrix is a dried, cross-linked foam. The matrix is not lyophilized. The method comprises foaming the composition, crosslinking the composition and drying the composition. Matrices disclosed herein are useful as wound dressings and treating wounds. 1. A matrix comprising a biomolecule; wherein the matrix is a dried , cross-linked foam.2. The matrix of claim 1 , wherein the matrix is non-lyophilized.3. The matrix of claim 1 , wherein the biomolecule is selected from the group consisting of gelatin claim 1 , collagen claim 1 , elastin claim 1 , and combinations thereof.4. The matrix of claim 1 , wherein the biomolecule is present at about 40% to about 80% (w/w).5. The matrix of claim 1 , further comprising at least two layers claim 1 , wherein each layer is independently homogenous or non-homogenous.6. The matrix of claim 1 , wherein the matrix is free of a hardened and/or compacted skin on a surface of the matrix.7. The matrix of claim 1 , further comprising at least one biocompatible polymer selected from the group consisting of polyethylene glycol claim 1 , poly-L-lysine claim 1 , alginate claim 1 , chitosan claim 1 , hyaluronic acid claim 1 , chondroitin sulfate claim 1 , pectin claim 1 , cellulose claim 1 , carboxymethylcellulose and mixtures thereof claim 1 , wherein the biocompatible polymer is present in about 0.4% to about 25% (w/w).8. The matrix of claim 1 , having a pore size ranging from about 100 μm to about 750 μm claim 1 , an absorption capacity of about 20 times to about 50 times a dry weight of the dried claim 1 , crosslinked foam matrix claim 1 , and/or a thickness of at least 1 mm.9. The matrix of claim 1 , further comprising an active agent selected from the group consisting of an antimicrobial agent claim 1 , an analgesic agent claim 1 , an anti-adhesion compound claim 1 , an anti-tumor drug claim 1 , an anti-proliferative drug ...

CURED BIODEGRADABLE MICROPARTICLES AND SCAFFOLDS AND METHODS OF MAKING AND USING THE SAME

A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores. 1. A method of forming a plurality of cured microparticles comprising:providing a composition comprising a poly(glycerol sebacate) resin in an uncured state; andforming the composition into a plurality of uncured microparticles, the plurality of uncured microparticles being free of a photo-induced crosslinker, and curing the plurality of uncured microparticles to form the plurality of cured microparticles.2. The method of claim 1 , wherein the forming comprises combining the composition with a phase-incompatible liquid and suspending the plurality of uncured microparticles in a matrix of the phase-incompatible liquid.3. The method of claim 2 , wherein the phase-incompatible liquid is an oil.4. The method of claim 1 , wherein the forming comprises shear mixing the composition in a phase-incompatible liquid.5. The method of claim 1 , wherein the forming comprises adding the composition into an aqueous solution to create a first emulsion and mixing the first emulsion into a phase-incompatible liquid to form a second emulsion.6. The method of claim 1 , wherein the forming comprises adding the composition into an alginate solution ...

Method Of Production Of New Polymeric Material

The present invention relates to a material as interpenetrating polymer network (IPN) associating a gel with a co-network of functionalized synthetic polymer and functionalized protein as well as a method of the manufacture of such a material. In particular, the invention relates to a material as interpenetrating polymer network associating a fibrin gel with a co-network of polyvinylalcohol and albumin thank to methacrylate bridges, with improved biodegradability properties. 1. Method for preparing a material as interpenetrating polymer network (IPN) associating a gel with a co-network of functionalized synthetic polymer crosslinked with a functionalized protein , comprising the steps of: a. a gel forming solution or a gel forming precursor solution,', 'b. a synthetic polymer selected in the group consisting of polyvinyl alcohol (PVA), polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL), poly(N-vinylpyrolidone), poly(2-hydroxy ethyl methacrylate) (PHEMA), polyethyleneoxide (PEO), and derivatives thereof, wherein the polymer is functionalized with grafted chemical groups X, X being selected in the group consisting of acrylate, methacrylate, vinyl, allyl and styrene and their derivatives,', 'c. a protein functionalized with grafted chemical groups X, wherein X is has the same meaning then in b)', 'd. a polymerization initiator,, 'i) preparing a first mixture by introducing into a buffer'}ii) preparing a second reaction mixture by optionally addition a gelification activator of the formation of the gel to the first mixture prepared in i),iii) incubating the reaction mixture obtained in i) or in ii) at a temperature and during a time sufficient to allow formation of the gel, andiv) performing a polymerizing and crosslinking of the functionalized synthetic polymer with the functionalized protein.2. Method according to wherein the gel is a physical fibrin gel and the gel forming precursor solution is fibrinogen solution.3. Method according to wherein ...

MULTI-COMPONENT ELECTROSPUN FIBER SCAFFOLDS

A scaffold may comprise a first polymeric electrospun fiber comprising a first material having a first degradation rate, and a second polymeric electrospun fiber comprising a second material having a second degradation rate different from the first degradation rate. The first degradation rate may substantially correspond to a cell infiltration rate, and the second degradation rate may be slower than the first degradation rate. Such a scaffold may be manufactured by electrospinning a first polymer fiber having a first degradation rate by ejecting a first polymer solution from a first polymer injection system onto a mandrel, and electrospinning a second polymer fiber having a second degradation rate different from the first degradation rate by ejecting a second polymer solution from a second polymer injection system onto a mandrel. Wound healing may be improved by applying such a scaffold to a portion of a wound. 1. A method of improving wound healing , comprising: a first polymeric electrospun fiber consisting of a first material; and', 'a second polymeric electrospun fiber consisting of a second material;, 'applying to a portion of a wound a scaffold comprisingwherein the first polymeric electrospun fiber has a diameter from about 0.5 μm to about 5 μm, and is configured to completely degrade within a first period of time in phosphate buffered saline at about 37 degrees Celsius;wherein the second polymeric electrospun fiber has a diameter from about 0.5 μm to about 5 μm, and is configured to completely degrade within a second period of time in phosphate buffered saline at about 37 degrees Celsius; andwherein the first period of time is from about 1 week to about 4 weeks, and wherein the second period of time is from about 4 weeks to about 24 weeks.2. The method of claim 1 , wherein the first material and the second material are independently selected from the group consisting of polycaprolactone claim 1 , chitosan claim 1 , polydioxanone claim 1 , polyglycolide claim ...

PENDANT HYDROPHILE BEARING BIODEGRADABLE COMPOSITIONS AND RELATED DEVICES

A composition comprising at least one polymer having the structure A-B-A′, wherein A and A′ may be the same or different and each is a degradable polyester component and wherein B is the reaction product resulting from the reaction between a diol, having one or more pendant oligomeric or polymeric groups, and A and A′. Additionally, a bioresorbable patch comprising: (a) an adhesion barrier component comprising the composition in the form of a film; and (b) an adhesive component comprising (i) at least one synthetic adhesive polymer and/or (ii) at least one polysaccharide. Also, a method of wound healing, comprising administering the composition or apply the patch to a patient. 1. A bioresorbable patch comprising:(a) an adhesion barrier component comprising, in the form of a patch, a composition comprising at least one polymer having the structure A-B-A′, wherein A and A′ may be the same or different and each is a degradable polyester component and wherein B is the reaction product resulting from the reaction between A and A′ and a diol having one or more pendant oligomeric or polymeric groups; and (i) at least one synthetic adhesive polymer; and/or', '(ii) at least one polysaccharide., '(b) an adhesive component comprising2. The bioresorbable patch of claim 1 , wherein said adhesive polymer is at least one synthetic polymer member selected from the group consisting of claim 1 , polyvinyllactam claim 1 , polyethyleneglycol claim 1 , polyethylene glycol-polypropylene glycol copolymers claim 1 , vinyl acetate homo and copolymers claim 1 , and poly(vinyl alcohol) and blends thereof.3. The bioresorbable patch of claim 1 , wherein said polysaccharide is at least one member selected from the group consisting of claim 1 , starch claim 1 , dextran claim 1 , agar claim 1 , cellulose claim 1 , carboxymethyl cellulose (CMC) claim 1 , hydroxypropylcellulose (HPC) claim 1 , chitin claim 1 , chitosan claim 1 , alginic acid claim 1 , hyaluronic acid claim 1 , chondroitin sulfate ...

MEDICAL DEVICE AND METHOD FOR THE PRODUCTION THEREOF

A medical device in the form of a nonwoven wound dressing includes rotospun fibers including at least one synthetic and bioabsorbable polymer and at least one hydrophilic and/or tissue-adhesive polymer, and a method of producing the medical device including using rotospinning to produce fibers from a fiber raw material including at least one synthetic and bioabsorbable polymer and at least one hydrophilic and/or tissue-adhesive polymer. 118-. (canceled)19. A medical device in the form of a nonwoven wound dressing comprising rotospun fibers comprising at least one synthetic and bioabsorbable polymer and at least one hydrophilic and/or tissue-adhesive polymer.20. The medical device as claimed in claim 19 , wherein the device comprises rotospun fibers comprising mutually different fractions of the at least one synthetic and bioabsorbable polymer and/or the at least one hydrophilic and/or tissue-adhesive polymer.21. The medical device as claimed in claim 19 , wherein the device comprises rotospun fibrous layers differing from each other in relation to a fiber fraction of the at least one synthetic and bioabsorbable polymer and/or the at least one hydrophilic and/or tissue-adhesive polymer.22. The medical device as claimed in claim 19 , wherein the device comprises at least one rotospun fibrous layer whose fibers comprise a higher fraction of the at least one synthetic and bioabsorbable polymer than of the at least one hydrophilic and/or tissue-adhesive polymer.23. The medical device as claimed in claim 19 , wherein the device comprises at least one rotospun fibrous layer whose fibers comprise a smaller fraction of the at least one synthetic and bioabsorbable polymer than of the at least one hydrophilic and/or tissue-adhesive polymer.24. The medical device as claimed in claim 19 , wherein the device comprises at least one rotospun fibrous layer whose fibers comprise the at least one synthetic and bioabsorbable polymer claim 19 , but not the at least one hydrophilic and/ ...

Degradable hemostatic sponge and preparation method and use thereof, and degradable drug-loaded hemostatic sponge

The present disclosure belongs to the technical field of hemostatic materials, and specifically relates to a degradable hemostatic sponge and a preparation method and use thereof, and a degradable drug-loaded hemostatic sponge. The degradable hemostatic sponge provided by the present disclosure is prepared from raw materials including a crosslinking-modified starch and a cellulose through freeze-drying, where a mass ratio of the crosslinking-modified starch to the cellulose is (0.2-5):1. The degradable hemostatic sponge provided by the present disclosure has a high water-absorbing rate and a large water-absorbing capacity, shows a high support strength and a long support time after water absorption, and is made from plant-derived raw materials and thus may be completely biodegraded. The degradable drug-loaded starch hemostatic sponge provided by the present disclosure has a drug-loaded coating attached to a surface of the sponge, where the drug is slowly released while a support is maintained.

Oxygen-generating compositions for enhancing cell and tissue survival in vivo

A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

ABSORBABLE COPOLYMERS WITH IMPROVED THERMAL STABILITY

The present invention relates to absorbable block copolymers with improved characteristics including thermal stability, molecular weight consistency, inherent viscosity retention following melt extrusion, and fibers made from the polymers exhibit increased strength. 1. An absorbable aliphatic polyester copolymer comprising:a polyaxial core, with at least three axes, including a pre-polymer;wherein the at least three axes comprise polymeric chains;at least one flexible linking segment; andat least one polymeric end graft comprising repeat units derived from at least one cyclic monomer capable of crystallization, the at least one polymeric end graft attached to each of the at least three axes.2. The absorbable aliphatic polyester copolymer of claim 1 , wherein the polyaxial core comprises crystallizable polymeric chain segments.3. The absorbable aliphatic polyester copolymer of claim 1 , wherein the polyaxial core comprises amorphous chain segments.4. The absorbable aliphatic polyester copolymer of claim 1 , wherein the flexible linking segment and the crystallizable cyclic monomer share a common monomer.5. The absorbable aliphatic polyester copolymer of claim 1 , wherein the flexible linking segments are comprised of the same prepolymer as the polyaxial core and the same crystallizable cyclic monomer as the at least one polymeric end grafts.6. The absorbable aliphatic polyester copolymer of claim 1 , wherein the prepolymer may be a homopolymer claim 1 , copolymer or terpolymer formed from the group consisting of L claim 1 ,L-lactide and D claim 1 ,L-lactide claim 1 , glycolide claim 1 , substituted glycolides claim 1 , para-dioxanone claim 1 , 1 claim 1 ,5-dioxepan-2-one claim 1 , trimethylene carbonate claim 1 , epsilon-caprolactone claim 1 , alpha-Angelica lactone claim 1 , gamma-valerolactone and delta-valerolactone claim 1 , or combinations thereof.7. The absorbable aliphatic polyester copolymer of claim 6 , wherein the pre-polymer is derived from epsilon- ...

Resorbable Laparoscopically Deployable Hemostat

The present invention is directed to a resorbable hemostatic nonwoven felt suitable for use in laparoscopic procedures and to methods for manufacturing said felt. 1. A resorbable hemostatic dressing comprising a single layer of three-dimensionally entangled nonwoven felt that is not separable into distinct layers by hand consisting essentially of oxidized cellulose fibers , wherein the felt has sufficient mechanical strength and flexibility to retain its structural integrity when deployed laparoscopically.29-. (canceled)10. A method of manufacturing the resorbable hemostatic nonwoven dressing of claim 1 , said method comprising the steps ofa) providing cellulose yarn having filaments of minimal twist;b) forming a multi-yarn, single feed circular knitted cellulose fabric having minimal twist;c) scouring the cellulose fabric;d) oxidizing the scoured fabric;e) pliabilizing the oxidized fabric;f) de-knitting the pliabilized fabric to form a continuous strand having a crimp from about 5 crimps/inch to about 12 crimps/inch;g) cutting the continuous strand to form staples, said staples having length from about 1½ to about 4¼ inches;h) carding the staples into a carded batt;i) needle-punching and three-dimensionally entangling the carded batt to form a single layer non-woven felt.11. The method according to claim 10 , wherein the steps of de-knitting and cutting are performed at low tension or minimal time at high tension.12. The method according to claim 10 , wherein the step of de-knitting is performed without subsequent spooling and followed immediately by cutting.13. The method according to claim 10 , wherein the carded batt comprises approximately 10 to 17 layers of carded web.14. The method according to claim 13 , wherein the carded batt comprises about 12 layers of carded web. This application is a Non-Provisional claiming priority from U.S. Provisional Application No. 61/412120, which was filed on Nov. 10, 2010. The complete disclosures of the aforementioned related ...

ANTIOXIDANT AND ANTIMICROBIAL WOUND DRESSING MATERIALS

A wound dressing material may include a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may include collagen and/or oxidized regenerated cellulose complexed to Ag+, and the dyestuff may, for example, be an aniline or acridine dye. Also disclosed are methods of making such materials, and wound dressings that include such materials. 1. A wound dressing material comprising a polymeric substrate , a silver salt , and a dyestuff to photostabilize the silver salt.2. A wound dressing material according to claim 1 , wherein the substrate comprises a solid bioabsorbable material claim 1 , preferably selected from the group consisting of collagens claim 1 , oxidized celluloses claim 1 , chitosans claim 1 , galactomannans claim 1 , glycosaminoglycans claim 1 , and mixtures thereof.3. A wound dressing material according to claim 2 , wherein the substrate comprises a solid bioabsorbable material selected from the group consisting of collagens claim 2 , oxidized celluloses claim 2 , chitosans claim 2 , and mixtures thereof.4. A wound dressing material according to claim 1 , wherein the substrate is selected from the group consisting of celluloses claim 1 , alginates claim 1 , polyacrylates claim 1 , polyurethanes claim 1 , polyamides claim 1 , and mixtures thereof.5. A wound dressing material according to claim 1 , wherein the wound dressing material is in the form of a continuous solid sheet claim 1 , an apertured solid sheet claim 1 , a web claim 1 , a woven fabric claim 1 , a knitted fabric claim 1 , a nonwoven fabric claim 1 , a freeze-dried sponge or a solvent-dried sponge.6. A wound dressing material according to claim 1 , wherein the polymeric substrate comprises an anionic polymer claim 1 , and said silver salt comprises a salt of Ag with the anionic polymer.7. A wound dressing material according to claim 1 , wherein the composition comprises from about 0.01 wt. % to about 5 wt. % of silver claim 1 , based on the dry ...

Hemostatic Pad Assembly Kit and Method

The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue. 1. A hemostatic wound treatment device comprising:a bioabsorbable scaffold having a wound facing surface and an opposing surface; said scaffold wetted with a biocompatible liquid that is not blood or plasma; anda hemostatic powder that adheres by moisture to at least the wound facing surface of said bioabsorbable scaffold.2. The hemostatic wound treatment device of wherein the hemostatic powder comprises a mixture of dry fibrinogen and dry thrombin.3. The hemostatic wound treatment device of wherein the hemostatic powder comprises dry fibrinogen.4. The hemostatic wound treatment device of wherein the hemostatic powder comprises dry thrombin.5. The hemostatic wound treatment device according to wherein the biocompatible liquid is selected from the group consisting of an aqueous solution claim 1 , normal saline claim 1 , ethanol claim 1 , and ethanol-water mixture.6. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises a hemostatic agent.7. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises thrombin claim 6 , fibrinogen claim 6 , hemostasis promoting agents claim 6 , growth factors claim 6 , calcium salts claim 6 , absorbable disaggregation aids claim 6 , bulking agents claim 6 , gelatin claim 6 , collagen claim 6 , and combinations thereof.8. The hemostatic wound treatment device according to wherein the biocompatible liquid comprises proteins claim 7 , prothrombin claim 7 , fibrin claim 7 , fibronectin claim 7 , heparinase claim 7 , Factor X/Xa claim 7 , Factor VII/VIIa claim 7 , Factor IX/IXa claim 7 , Factor XI/XIa claim 7 , Factor XII/XIIa claim 7 , tissue factor ...

NOVEL HEMOSTATIC PATCH AND USES THEREOF

Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch. 19.-. (canceled)10. A hemostatic patch , wherein the patch comprises a mucoadhesive and a formulation of vasoconstrictant nanoparticles , wherein the vasoconstrictant nanoparticle comprises a vasoconstrictor selected from , Neuropeptide Y , Neuropeptide Y analogues , epinephrine , norepinephrine , vasopressin , phenylephrine , pseudoephedrine , metaraminol , Peptide YY , Angiotensin II , Muscarinic agonists , Endothelin; and Andrenergic agonists , wherein the vasoconstrictor is encapsulated or immobilized on a bioabsorbable polymer.11. The hemostatic patch of claim 10 , wherein the bioabsorbable polymer comprises chitosan.12. The hemostatic patch of claim 10 , wherein the polymer comprises poly(lactic-co-glycolic acid) (PLGA).13. The hemostatic patch of claim 10 , wherein the polymer comprises chitosan crosslinked using glutaraldehyde.14. The hemostatic patch of claim 10 , wherein the polymer comprises chitosan crosslinked to PLGA.15. The hemostatic patch of claim 10 , wherein the vasoconstrictant nanoparticle comprises a vasoconstrictor selected from claim 10 , Neuropeptide Y claim 10 , Neuropeptide Y analogues claim 10 , epinephrine claim 10 , norepinephrine claim 10 , vasopres sin claim 10 , phenylephrine claim 10 , pseudoephedrine claim 10 , metaraminol claim 10 , Peptide YY claim 10 , Angiotensin II claim 10 , Muscarinic agonists claim 10 , Endothelin; and/or claim 10 , Andrenergic agonists) claim 10 , and the vasoconstrictor is covalently bound to the polymer.16. (canceled)17. The hemostatic patch of claim 11 , wherein the chitosan ...

BIORESORBABLE WOUND DRESSING

The present invention is directed to novel non-woven fabrics containing growth and differentiation factor proteins. Said fabrics are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues. Furthermore, the invention provides wound dressings, pads or implants comprising the novel non-woven fabrics. 1. A method of facilitating healing of a damaged mammalian tissue , comprising applying to the damaged mammalian tissue a non-woven fabric ,wherein the non-woven fabric comprises fibres of a fibre raw material comprising bioresorbable and/or biocompatible polymers, the fibres including at least one biologically active substance, which is distributed in the fibres,wherein the biologically active substance is a GDF-5-related protein,wherein the GDF-5-related protein comprises a cystine-knot-domain with an amino acid identity of at least 60% to the 102 aa-cystine-knot-domain of human GDF-5 according to amino acids 400-501 of SEQ ID NO:2, andwherein the GDF-5-related protein which is distributed in the fibres is added to the fibre raw material before forming of the fibres.2. The method of claim 1 , wherein the GDF-5-related protein is additionally distributed on the fibres.3. The method of claim 1 , wherein the fibre raw material is selected from the group consisting of natural polymers claim 1 , synthetic polymers claim 1 , polymers derived from fossil raw materials claim 1 , each of which may be modified or unmodified claim 1 , and combinations thereof.4. The method of claim 1 , the non-woven fabric comprising another substance dispersed into the fibres.5. The method of claim 1 , wherein the non-woven fabric is produced by a rotation spinning method.6. The method of claim 1 , wherein at least some of the fibres are nanofibres.7. The method of claim 1 , wherein at least 10% of the biologically active substance is eluted from the non-woven fabric within 3 to 7 days after application of the non-woven fabric to the damaged ...

WOUND DRESSING COMPRISING HYALURONIC ACID-CALCIUM AND POLYLYSINE AND MANUFACTURING METHOD THEREFOR

The present invention relates to a wound dressing comprising hyaluronic acid-calcium and polylysine, and a manufacturing method therefor, the method comprising: (1) a step for adjusting each of the pH values of a hyaluronic acid-calcium salt and a polylysine aqueous solution to 8.4 or higher, and then mixing the hyaluronic acid-calcium salt and the polylysine aqueous solution to obtain a mixture liquid; and (2) obtaining a wound dressing from the mixture liquid obtained in Step (1). 1. A wound dressing comprising hyaluronic acid-calcium and polylysine.2. The wound dressing according to claim 1 , comprising the hyaluronic acid-calcium and polylysine in a ratio of 4:1 to 1:1.5 by weight.3. The wound dressing according to claim 1 , comprising the hyaluronic acid-calcium and polylysine in a ratio of 2:1 to 4:3 by weight.4. The wound dressing according to claim 1 , comprising the hyaluronic acid-calcium and polylysine in a ratio of 2:1 to 1:1.5 by weight.5. The wound dressing according to claim 1 , wherein the hyaluronic acid has a molecular weight of 2×10to 3×10Da.6. The wound dressing according to claim 1 , wherein the wound dressing is in a form of liquid claim 1 , foam or film.7. A method for preparing a wound dressing according to claim 1 , comprising:(1) mixing an aqueous hyaluronic acid-calcium salt adjusted to pH 8.4 or higher with an aqueous polylysine adjusted to pH 8.4 or higher, and(2) obtaining a wound dressing from a mixed solution obtained in Step (1).8. The method according to claim 7 , wherein each of the pH values of the aqueous hyaluronic acid-calcium salt and the aqueous polylysine is adjusted to a range of 8.4 to 9.0 in Step (1).9. The method according to claim 7 , wherein a liquid-type wound dressing is obtained from the mixed solution in Step (2).10. The method according to claim 7 , wherein the mixed solution is freeze-dried to obtain a foam-type wound dressing in Step (2).11. The method according to claim 7 , wherein the mixed solution is applied ...

BIOMEDICAL PATCHES WITH SPATIALLY ARRANGED FIBERS

A three-dimensional electrospun nanofiber scaffold for use in repairing a defect in a tissue substrate is provided. The three-dimensional electrospun nanofiber scaffold includes a first layer formed by a first plurality of electrospun polymeric fibers and a second layer formed by a second plurality of electrospun polymeric fibers. The second layer is coupled to the first layer using a coupling process and includes a plurality of varying densities formed by the second plurality of electrospun polymeric fibers. The first and second layers are configured to degrade via hydrolysis after at least one of a predetermined time or an environmental condition. The three-dimensional electrospun nanofiber scaffold is configured to be applied to the tissue substrate containing the defect. 1. A three-dimensional electrospun biomedical patch for facilitating tissue repair , the three-dimensional electrospun biomedical patch comprising:a first polymeric scaffold comprising a first structure of deposited electrospun fibers, the first structure of deposited electrospun fibers comprising a plurality of deposited electrospun fibers extending in a plurality of directions in three dimensions to facilitate cellular migration for a first period of time upon application of the three-dimensional electrospun biomedical patch to a tissue, wherein the first period of time is less than twelve months;a second polymeric scaffold comprising a second structure of deposited electrospun fibers, the second polymeric scaffold overlaid on the first polymeric scaffold, the second polymeric scaffold comprising one or more portions with a higher deposition of fibers than one or more portions of the first polymeric scaffold, the second structure of deposited electrospun fibers comprising the plurality of deposited electrospun fibers configured to provide structural reinforcement for a second period of time upon application of the three-dimensional electrospun biomedical patch to the tissue, wherein the second ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer conisisting essentially of thrombin and a fibrinogen component , wherein said thrombin is present an amount between about 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a hacking material.4. The solid dressing of claim 2 , wherein said support layer comprises an internal support material.5. The solid dressing of claim 2 , wherein said support layer comprises a resorbable material.6. The solid dressing of claim 2 , wherein said support layer comprises a non-resorbable material.7. (canceled)8. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.911-. (canceled)12. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin crosslinker and/ or a source of calcium ions.13. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.1417-. (canceled)18. The solid dressing of claim 1 , wherein said haemostatic layer also contains at least one therapeutic supplement selected from the group consisting of antibiotics claim 1 , anticoagulants claim 1 , steroids claim 1 , cardiovascular drugs claim 1 , growth factors ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing comprising a solid haemostatic layer wherein said solid haemostatic layer comprises dried fibrinogen component and thrombin , said dried fibrinogen and thrombin being dried from a single aqueous mixture of fibrinogen and thrombin.2. A solid dressing comprising a haemostatic layer comprising substantially unreacted fibrinogen component and thrombin , wherein said fibrinogen component and said thrombin are dried from a single aqueous solution forming said solid haemostatic layer; and wherein said fibrinogen component and thrombin within the solid are substantially unreacted until said solid dressing comes into contact with an aqueous fluid.3. The solid dressing of comprising at least two haemostatic layers.4. The solid dressing of or claim 1 , further comprising at least one support layer.5. The solid dressing of claim 4 , wherein said support layer comprises a backing material.6. The solid dressing of claim 4 , wherein said support layer comprises an internal support material.7. The solid dressing of claim 4 , wherein said support layer comprises a resorbable material.8. The solid dressing of claim 4 , wherein said support layer comprises a non-resorbable material.9. (canceled)10. The solid dressing of claim 4 , further comprising at least one physiologically acceptable adhesive between said haemostatic layer and said backing layer.1113-. (canceled)14. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin ...

COLLAGEN/ORC DRESSING ENCAPSULATED WITHIN A BIORESORBABLE ENVELOPE

Wound dressing compositions comprising of a bioresorbable sponge encapsulated within a polysaccharide envelope. The bioresorbable sponge is preferably comprised of collagen and oxidised regenerated cellulose. The outer polysaccharide envelope is preferably comprised of chitosan. The outer polysaccharide envelope functions to modulate the rate at which the bioresorable sponge breaks down within a wound. 1. A wound dressing comprising(a) a bioresorbable sponge having a wound-facing surface and an opposite bottom surface, the bioresorbable sponge comprising oxidized regenerated cellulose (ORC) and collagen; and(b) a bioresorbable top sheet covering the wound-facing surface of the bioresorbable sponge, the top sheet comprising a polysaccharide polymer.2. The wound dressing according to claim 1 , wherein the polysaccharide polymer is selected from the group consisting of alginates claim 1 , chitosan claim 1 , chitin claim 1 , guar gums claim 1 , starch derivatives claim 1 , cellulose derivatives claim 1 , glycosaminoglycans claim 1 , chondroitin sulfate claim 1 , heparin sulfate claim 1 , and a mixture of any two or more thereof.3. (canceled)4. The wound dressing according to claim 1 , wherein an aqueous solution used to generate the top sheet has a solids content of from about 1% to about 5%.5. (canceled)6. The wound dressing according to claim 1 , further comprising a bottom sheet.7. The wound dressing according to claim 6 , wherein the bottom sheet comprises a resorbable polysaccharide.8. The wound dressing according to claim 6 , wherein the top sheet and the bottom sheet are bonded so as to substantially encapsulate the bioresorbable sponge.911-. (canceled)12. The wound dressing according to claim 1 , wherein the top sheet has a perforation density of about 4/cm claim 1 , and the perforations have an average diameter of from about 0.02 cm to about 0.4 cm.13. The wound dressing according to claim 1 , wherein the bioresorbable sponge further comprises a structural ...

HYDROGELS WITH BIODEGRADABLE CROSSLINKING

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. 2. The biodegradable hydrogel of wherein each said functional group independently comprises N claim 1 , NH claim 1 , NH—COBu claim 1 , SH claim 1 , SBu claim 1 , maleimide claim 1 , COH claim 1 , COBu claim 1 , 1 claim 1 ,3-diene claim 1 , cyclopentadiene claim 1 , furan claim 1 , alkyne claim 1 , cyclooctyne claim 1 , acrylate claim 1 , or acrylamide.3. The biodegradable hydrogel of wherein in Formula (1){'sup': '2', 'Ris H; and/or'}{'sup': '5', 'sub': 2', 'n, 'one of Ris H and the other is (CH)Z wherein n is 1-6 and Z includes said functional group.'}4. The biodegradable hydrogel of wherein in Formula (1) wherein Ris CN or SOR.5. The biodegradable hydrogel of wherein the first and/or second polymer comprises the formula [—(CH)(CHCHO)]Q claim 1 , whereinn is 10-1000;s is 0-2;t is 2, 4, 8, 16 or 32 and represents the number of arms of said polymer; andQ is a core group having a valency=t.6. The biodegradable hydrogel of wherein Q is pentaerythritol claim 5 , tripentaerythritol claim 5 , or hexaglycerin. This application is a continuation of U.S. patent application Ser. No. 15/486,215, filed 12 Apr. 2017, which is a continuation of U.S. patent application Ser. No. 14/343,819, having an international filing date of 7 Sep. 2012, which is the national phase of PCT application PCT/US2012/054278 having an international filing date of 7 Sep. 2012, which claims benefit of U.S. Application Ser. No. 61/531,990 filed 7 Sep. 2011. The contents of the above patent applications are incorporated by reference herein in their entirety.The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 670572000602SeqList.txt, ...

HYDROGELS WITH BIODEGRADABLE CROSSLINKING

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. 1. A drug-releasing degradable hydrogel prepared by a method that comprises(a) providing a first multi-armed polymer wherein each arm is terminated by a group comprising orthogonal first and second functional groups, which first orthogonal functional group is different from said second orthogonal functional group;(b) reacting said first multi-armed polymer of (a) with a linker-drug conjugate wherein said conjugate comprises a third functional group that reacts with only the first orthogonal functional group to obtain a derivatized first polymer; and(c) reacting the derivatized first polymer obtained in (b) with a crosslinker coupled to a second multi-armed polymer wherein said crosslinker comprises a fourth functional group that reacts with only the second orthogonal functional group present on said derivatized polymer to obtain said drug-releasing degradable hydrogel, or(d) reacting said first multi-armed polymer of (a) with a crosslinker coupled to a second multi-armed polymer wherein said crosslinker comprises a fourth functional group that reacts only with the second orthogonal functional group to obtain a crosslinked polymer, and(e) reacting the crosslinked polymer of (d) with a linker-drug conjugate, wherein said conjugate comprises a third functional group that reacts with only the first orthogonal functional group to obtain a said drug-releasing degradable hydrogel.2. The method of wherein the linker-drug conjugate and the cross linker are degradable by a β-elimination reaction.3. The method of wherein each said orthogonal functional group independently comprises N claim 1 , NH claim 1 , NH—COBu claim 1 , SH claim 1 , SBu claim 1 , maleimide claim 1 , COH claim 1 , COBu claim 1 , 1 claim 1 ,3-diene claim 1 , ...

MATERIAL FOR ADHESION PREVENTION

A material for adhesion prevention can be adhered to biological tissue with certainty and has improved tissue adhesiveness and biodegradability. Such material for adhesion prevention is composed of: a 1- to 1,000-μm-thick water-soluble support layer comprising a water-soluble polymer; and a 1- to 1,000-μm-thick adhesion prevention layer comprising a biodegradable polymer. The biodegradable polymer has a structure in which a branched polyalkylene glycol comprising 3 to 8 terminal hydroxyl groups per molecule is bound to a polyhydroxy alkanoic acid, and a mass ratio of the branched polyalkylene glycol relative to the total mass is 1% to 30%. 19-. (canceled)10. A material for adhesion prevention composed of a 1 to 1 ,000 μm-thick water-soluble support layer comprising a water-soluble polymer and a 10 to 1 ,000 nm-thick adhesion prevention layer comprising a biodegradable polymer , wherein the biodegradable polymer is composed of a branched polyalkylene glycol comprising 3 to 8 terminal hydroxyl groups per molecule bound to a polyhydroxy alkanoic acid and the mass ratio of the branched polyalkylene glycol relative to the total mass is 1% to 40%.11. The material according to claim 10 , wherein the branched polyalkylene glycol is composed of linear polyalkylene glycol bound to a polyhydric alcohol.12. The material according to claim 10 , wherein the polyhydroxy alkanoic acid is a homopolymer of monomers selected from the group consisting of lactic acid claim 10 , glycolic acid claim 10 , and caproic acid or a copolymer of two or more of the monomers.15. The material according to claim 10 , wherein the polyhydroxy alkanoic acid in the biodegradable polymer represented by Formulae (I) and (IV) is a copolymer of lactic acid and glycolic acid and the ratio of the molar number of the lactic acid relative to the molar number of the glycolic acid in the biodegradable polymer is 3.0 to 5.0.16. The material according to claim 10 , wherein the water-soluble polymer is a ...

BIOPOLYMER MULTI-LAYER MULTI-FUNCTIONAL MEDICAL DRESSING AND METHOD OF MAKING SAME

The Technology described herein applies to medical dressings designed to heal wounds in the area of advanced wound care, inclusive of Negative Pressure Wound Therapy (NPWT), and describes novel wound healing absorbent scaffolds and dressing based on natural and naturally-derived material and fibers, preferentially poly (lactic) acid fibers and alginate materials. 1. A medical dressing comprising a biopolymer layered structure , the biopolymer layered structure comprising:a biodegradable, bioresorbable layer comprising a plurality of biodegradable, bioresorbable fibers, wherein the fibers are oriented to provide compression resistance and maintain paths for liquid-flow and air-flow, and a bioresorbable, biodegradable hydrophilic surface coating on a substantial number of the fibers; the fibers incorporating one or more bioactive agents.2. The medical dressing of claim 1 , wherein the layered structure comprises one or more natural fibers selected from the group consisting of cotton claim 1 , bamboo and sisal.3. The medical dressing of claim 1 , wherein the layered structure comprises one or more fibers manufactured from natural sources selected from the group consisting of polylactide claim 1 , polyglycolide claim 1 , poly-L-lactide claim 1 , poly-DL-lactide claim 1 , polycaprolactone claim 1 , polyhydroxyalkanoate claim 1 , viscose claim 1 , polyethylene terephthalate and polypropylene.4. The medical dressing of claim 3 , wherein the fibers comprise polymers of polylactide.5. The medical dressing of claim 1 , wherein the bioresorbable hydrophilic surface coating is on a substantial number of the fibers located proximate to other layers of the medical dressing.6. The medical dressing of claim 1 , wherein each of the fibers in the plurality of fibers has a diameter of approximately 1 μM to 1 mm.7. The medical dressing of claim 6 , wherein each of the fibers in the plurality of fibers has a diameter of approximately 5 to 100 μM.8. The medical dressing of claim 1 , ...

HYDROPHILIC MEDICAL DEVICES

A medical device including a plasma-treated porous substrate that is functionalized to provide a hydrophilic surface, and a process for preparing such a medical device, are disclosed. The method includes plasma treating at least a portion of a surface of a porous substrate with a gas species selected from oxygen, nitrogen, argon, and combination thereof. The gas species is configured to functionalize the surface of the medical device and form a hydrophilic surface. 119-. (canceled)20. An absorbent surgical buttress , comprising a non-woven material having a plurality of fibers adhered to one another , the fibers being formed from a melt extruded bioabsorbable polymeric material , the non-woven material being plasma treated on at least a portion of a surface of the non-woven material so that the surface is chemically modified or functionalized , the non-woven material being cut into a desired shape for the surgical buttress.21. The absorbent surgical buttress according to claim 20 , wherein the fibers are formed from a polymeric material selected from the group consisting of lactide homopolymer claim 20 , glycolide homopolymer claim 20 , polydioxanone homopolymer claim 20 , glycolide trimethylene carbonate copolymer claim 20 , glycolide lactide copolymer claim 20 , glycolide dioxanone trimethylene carbonate claim 20 , and glycolide caprolactone trimethylene carbonate lactide.22. The absorbent surgical buttress according to claim 20 , wherein the fibers are formed from a polymeric material having a melting temperature of between about 180° C. and about 250° C.23. The absorbent surgical buttress according to claim 20 , wherein the fibers are formed from a polymeric material having a melting temperature of between about 80° C. and about 190° C.24. The absorbent surgical buttress according to claim 20 , wherein the non-woven material is cut into a shape corresponding to the shape of a linear surgical stapler.25. The absorbent surgical buttress according to claim 20 , ...

Degradable haemostat composition

In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid, which is present in the amount of 45-70% by weight of the haemostat composition. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

BIOMEDICAL FOAMS

The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used e.g. in the form of a plug or tampon, for instance for controlling bleeding, wound closure, prevent tissue adhesion and/or support tissue regeneration. The invention provides an absorbent foam, suitable for packing antrums or other cavities of the human or animal body, comprising a biodegradable synthetic polymer, which polymer preferably comprises —C(O)—O— groups in the backbone of the polymer, for instance polyurethane and/or polyester units combined with polyethers. 1. Biodegradable absorbent foam , suitable for packing antrums or other cavities of a human or animal body , comprising a phase-separated polymer including an amorphous segment and a crystalline segment and wherein said amorphous segment comprises a hydrophilic segment , wherein said amorphous segment comprises polyethyleneglycol , polypropyleneglycol or polybutylene glycol , and wherein said biodegradable absorbent foam has a complete fragmentation time ranging from 1 to 10 days.5. Biodegradable absorbent foam according to claim 4 , wherein said phase-separated polymer is obtained by reacting at least two different pre-polymers according to formula (III) with one or more diisocyanates of the formula (IV):{'br': None, 'O═N—R′—N═C═O\u2003\u2003(IV).'}7. Biodegradable absorbent foam according to claim 3 , wherein R′ is (CH) claim 3 , R″ is (CH) claim 3 , or both R′ and R″ are (CH).8. Biodegradable absorbent foam according to claim 3 , wherein at least one R is derived from a cyclic monomer of lactide (L claim 3 , D or LD) claim 3 , glycolide claim 3 , C-caprolactone claim 3 , ε-valerolactone claim 3 , trimethylene carbonate claim 3 , tetramethylene carbonate claim 3 , 1 claim 3 ,5-dioxepane-2-one claim 3 , para-dioxanone claim 3 , or combinations thereof.9. Biodegradable ...

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials. 1. A wound dressing material comprising: a wound dressing carrier , N-acetyl cysteine or a salt or derivative thereof; and a stabilized ascorbate.2. A wound dressing material according to claim 1 , wherein the material comprises from about 0.1 wt. % to about 20 wt. % of said N-acetyl cysteine or salts or derivatives thereof claim 1 , and from about 0.1 wt. % to about 20 wt. % of said stabilized ascorbate.3. A wound dressing material according to claim 2 , wherein the material comprises from about 1 wt. % to about 10 wt. % of said N-acetyl cysteine or salts or derivatives thereof claim 2 , and from about 1 wt. % to about 10 wt. % of said stabilized ascorbate.4. A wound dressing material according to claim 1 , wherein the weight ratio of N-acetyl cysteine or salts or derivatives thereof claim 1 , to said stabilized ascorbate is from about 1:4 to about 4:1.5. A wound dressing material according to claim 1 , wherein said stabilized ascorbate is selected from the group consisting of ascorbate 2-phosphate or polyphosphate compounds claim 1 , Trisodium-L-ascorbyl-2-monophosphate; 2-Phospho-L-ascorbic acid trisodium salt claim 1 , Magnesium Ascorbyl Phosphate (MAP) claim 1 , L-Ascorbic acid mono(dihydrogen phosphate) magnesium salt claim 1 , Magnesium L-ascorbic acid-2-phosphate claim 1 , trisodium-L-ascorbyl-2-polyphosphate claim 1 , and mixtures thereof.6. A wound dressing material according to claim 5 , wherein said stabilized ascorbate comprises or consists essentially of an ascorbate-2-polyphosphate.7. A wound dressing material according to claim 5 , wherein the material comprises N-acetyl cysteine and ascorbate-2- ...

Polymer substrate retinal patch coated with adhesives

Several embodiments disclosed herein relate to compositions and methods for treating or repairing damage to ocular tissue. In particular, several embodiments relate to patches that interact, e.g., by way of an adhesive, with damaged retinal tissue to repair or mend a hole, tear or detachment of the retina from underlying ocular tissue. Still additional embodiments relate to self-assembling patches.

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator , wherein said haemostatic layer is formed from a single aqueous solution containing said fibrinogen component and said fibrinogen activator.2. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator , wherein said haemostatic layer is cast as a single piece.3. The solid dressing of or , further comprising at least one support layer.4. The solid dressing of claim 3 , wherein said support layer comprises a backing material.5. The solid dressing of claim 3 , wherein said support layer comprises an internal support material.6. The solid dressing of claim 3 , wherein said support layer comprises a resorbable material.7. The solid dressing of claim 3 , wherein said support layer comprises a non-resorbable material.8. The solid dressing of claim 7 , wherein said non-resorbable material is selected from the group consisting of silicon polymers claim 7 , paper claim 7 , gauze and latexes.9. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.10. The solid dressing of claim 6 , wherein said resorbable material is selected from the group consisting of proteinaceous materials and ...

POLYMERIC MESH WITH SELECTIVE PERMEABILITY, FOR THE REPAIR AND REGENERATION OF TISSUES

The present application describes a polymeric mesh for the repair and regeneration of tissues from an organism that comprises pores wherein at least 70% of the pores of the said mesh have a size smaller than the one required to confine the cells of the said tissues, and wherein at least 70% of the pores of the said mesh has a size superior than the one needed for the passage of interstitial fluids of the said tissues; the degradation time of the said polymeric mesh within the organism is at least 8 weeks; the said polymeric mesh has an apparent tensile strength superior than 1 MPa; the said polymeric mesh has an apparent elastic modulus superior than 0.1 MPa. The mesh described in this application allows that the “new tissue” formed presents very similar properties to the ones of the damaged tissue. 125-. (canceled)26. A polymeric mesh for the repair and regeneration of tissues of an organism that comprises pores wherein at least 70% of the pores of the said mesh have a size smaller than the one required to confine the cells of the said tissues , and wherein at least 70% of the pores of the said mesh has a size more than the one needed for the passage of the interstitial fluids of the said tissues;wherein the degradation time of the said polymeric mesh within the organism is at least 8 weeks and the said polymeric mesh comprises:an apparent tensile strength between 2.15-4.38 MPa and an apparent elastic modulus between 8.58-27.87 MPa;an interconnected porosity ranging between 83-91%;in which 80-90% of the pores have a size ranging between 1.2-13.37 μm.27. The mesh claim 26 , according to claim 26 , wherein the degradation time of the said polymeric mesh is 8-26 weeks claim 26 , preferably 8-15 weeks.28. The mesh claim 26 , according to claim 26 , comprising at least one polymer selected from polycaprolactone claim 26 , polyglycolic acid claim 26 , polylactic acid claim 26 , chitosan claim 26 , alginate or dextran claim 26 , or combinations thereof.29. The mesh claim ...

Formulations for Wound Therapy

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention. 1. A pharmaceutical composition comprising an absorbable carrier of a biocompatible , biodegradable polymer and dispersed , at least partially through or on said absorbable carrier , microparticles comprising fibrinogen in an amount of from about 0.1-15 mg/cmand/or microparticles comprising thrombin in an amount of from about 0.01 to 500 IU/cm , wherein the microparticles further comprise a glassy carrier.2. The pharmaceutical composition according to claim 1 , wherein dispersed claim 1 , at least partially through or on said absorbable carrier claim 1 , is a mixture of microparticles comprising fibrinogen and microparticles comprising thrombin.3. The pharmaceutical composition according to claim 2 , wherein the glassy carrier of the microparticles comprises trehalose.4. The pharmaceutical composition according to wherein the microparticles are fixed on or fixed through said absorbable carrier.5. The pharmaceutical composition according to claim 1 , wherein the absorbable carrier is flexible or porous claim 1 , and the composition optionally further comprises a plasticizer claim 1 , binder or viscosifying agent.6. The pharmaceutical composition according to claim 5 , wherein the absorbable carrier is both flexible and porous.7. The pharmaceutical composition according to wherein the absorbable carrier comprises a biocompatible polymer selected from the group consisting of polysaccharides claim 1 , albumin claim 1 , a cellulose claim 1 , methylcellulose claim 1 , alkylhydroxyalkyl cellulose claim 1 , hydroxyalkyl cellulose claim 1 , cellulose sulfate claim 1 , salts of carboxymethyl cellulose claim 1 , carboxymethyl cellulose claim 1 , carboxyethyl cellulose claim 1 , oxidised cellulose; ...

CURED BIODEGRADABLE MICROPARTICLES AND SCAFFOLDS AND METHODS OF MAKING AND USING THE SAME

A method of forming cured microparticles includes providing a poly(glycerol sebacate) resin in an uncured state. The method also includes forming the composition into a plurality of uncured microparticles and curing the uncured microparticles to form the plurality of cured microparticles. The uncured microparticles are free of a photo-induced crosslinker. A method of forming a scaffold includes providing microparticles including poly(glycerol sebacate) in a three-dimensional arrangement. The method also includes stimulating the microparticles in the three-dimensional arrangement to sinter the microparticles, thereby forming the scaffold having a plurality of pores. A scaffold is formed of a plurality of microparticles including a poly(glycerol sebacate) thermoset resin in a three-dimensional arrangement. The scaffold has a plurality of pores. 1. A method of forming a plurality of cured microparticles comprising:providing a composition comprising a poly(glycerol sebacate) resin in an uncured state; andforming the composition into a plurality of uncured microparticles, the plurality of uncured microparticles being free of a photo-induced crosslinker, and curing the plurality of uncured microparticles to form the plurality of cured microparticles.2. The method of claim 1 , wherein the forming comprises combining the composition with a phase-incompatible liquid and suspending the plurality of uncured microparticles in a matrix of the phase-incompatible liquid.3. The method of claim 2 , wherein the phase-incompatible liquid is an oil.4. The method of claim 2 , wherein the phase-incompatible liquid is an elastomer.5. The method of claim 4 , wherein the elastomer is acrylic-based or isobutylene-based.6. The method of claim 1 , wherein the forming comprises shear mixing the composition in a phase-incompatible liquid.7. The method of claim 1 , wherein the forming comprises adding the composition into an aqueous solution to create a first emulsion and mixing the first ...

Hemostatic Dressings with Self-Assembling Peptide Hydrogels

Hemostatic dressings are synergistically used in conjunction with self-assembling peptide hydrogels to promote hemostasis at a target site. Related methods, kits, and devices for hemostasis are disclosed. 113.-. (canceled)14. A device for hemostasis , comprising: a substantially porous wound dressing; anda solution comprising a self-assembling peptide pervading the pores of the porous wound dressing, the self-assembling peptide comprising between about 7 amino acids and 32 amino acids in an effective amount and in an effective concentration for use in forming a hydrogel under physiological conditions to promote hemostasis.15. The device of claim 14 , wherein the solution is present in a volume of about 1 μL to 2 mL per 1 cmof porous wound dressing.16. The device of claim 14 , wherein the wound dressing and solution capable of promoting hemostasis on a wound having an initial bleeding score of 2 or higher claim 14 , as assessed on the World Health Organization (WHO) Bleeding Scale.17. The device of claim 16 , wherein the wound dressing and solution are capable of promoting hemostasis on a wound having an initial bleeding score of 3 or higher claim 16 , as assessed on the WHO Bleeding Scale.18. The device of claim 14 , wherein the self-assembling peptide is selected from the group consisting of RADA16 and IEIK13.19. The device of claim 14 , wherein the self-assembling peptide comprises KLD12.20. The device of claim 14 , wherein the self-assembling peptide comprises between about 12 to about 16 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid.23. The kit of claim 14 , wherein the wound dressing comprises cotton gauze.21. The device of claim 14 , wherein the solution is substantially free of cells and/or drugs.22. The device of claim 14 , wherein the wound dressing comprises a sponge claim 14 , a woven textile claim 14 , a non-woven textile claim 14 , a puff claim 14 , or a mixture thereof. One or more aspects relate to hemostatic ...

DISSOLVABLE HYDROGEL COMPOSITIONS FOR WOUND MANAGEMENT AND METHODS OF USE

The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound). 1. A method comprising:{'claim-ref': {'@idref': 'CLM-00029', 'claim 29'}, '(a) contacting a wound with a hydrogel composition of ; and'}(b) allowing the dissolvable hydrogel layer to adhere to tissue surrounding the wound.228.-. (canceled)29. A dissolvable hydrogel composition comprising: an adhesive hydrogel layer comprising a first water-soluble linear , branched and/or dendritic crosslinkable polymer and a second water-soluble linear , branched and/or dendritic crosslinkable polymer held together by covalent bonds formed between the first crosslinkable polymer and the second crosslinkable polymer , wherein the second crosslinkable polymer comprises at least two thioester linkages within its backbone.3031.-. (canceled)33. The dissolvable hydrogel composition of claim 29 , wherein the linear crosslinkable polymer comprises polyesters claim 29 , polyethers claim 29 , polyglycerols claim 29 , polypeptides claim 29 , polyether-esters claim 29 , polyamino acids claim 29 , polyester-amines claim 29 , polyurethanes claim 29 , polycarbonates claim 29 , polyamino alcohols claim 29 , thiols claim 29 , amines claim 29 , N-hydroxysuccinimide (NHS) moieties claim 29 , maleimide (MAL) moieties claim 29 , or any combinations thereof.34. The dissolvable hydrogel composition of claim 29 , wherein the branched crosslinkable polymer comprises polyesters claim 29 , polyethers ...

FORMULATIONS FOR WOUND THERAPY

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention. 1. A method of treating a wound or reducing bleeding at a haemorrhaging site , comprising administering to the wound or haemorrhaging site a pharmaceutical composition comprising an absorbable carrier of a biocompatible , biodegradable polymer and microparticles comprising fibrinogen in an amount of from about 0.1-15 mg/cmand/or microparticles comprising thrombin in an amount of from about 0.01 to 500 IU/cm , wherein the microparticles further comprise a glassy carrier , and wherein the microparticles are attached to said absorbable carrier.2. The method of claim 1 , wherein said treatment results in a time to hemostasis of less than about 10 minutes when administered to a wound or haemorrhaging site which exhibits a bleeding rate of greater than about 30 g/minute.3. The method of claim 1 , wherein the absorbable carrier consists essentially of a biocompatible claim 1 , biodegradable polymer selected from a cellulose claim 1 , polyurethane claim 1 , gelatin or collagen claim 1 , such as a collagen-sponge claim 1 , or a chitosan claim 1 , and amorphous fibrinogen or amorphous thrombin claim 1 , and the treatment is for tissue sealing claim 1 , tissue gluing or hemostasis.4. The method of claim 3 , wherein the amorphous fibrinogen or amorphous thrombin exhibit a degree of crystallinity of at most about 10% by weight of the microparticle population in the carrier.5. The method of wherein the treatment is for the topical treatment of a wound claim 3 , and the wound is selected from the group consisting of a) minor abrasions claim 3 , cuts claim 3 , scrapes claim 3 , scratches claim 3 , burns claim 3 , sunburns claim 3 , ulcers claim 3 , internal venous bleeding claim 3 , external venous ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cmof the wound facing surface of the dressing and 13.0 mg/cmof the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of fibrinogen and a solvent consisting of water and a fibrinogen activator wherein said haemostatic layer is substantially homogeneous , wherein said fibrinogen is present in an amount about 13.0 mg/cmof the wound facing surface of said dressing , and wherein the moisture content of said solid dressing is from 6% to 44%.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 2 , wherein said support layer comprises an internal support material.5. The solid dressing of ; wherein said support layer comprises a resorbable material.6. The solid dressing of claim 2 , wherein said support layer comprises a non resorbable material.7. (canceled)8. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.911-. (canceled)12. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin crosslinker and/or a source of calcium ions.13. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.1421-. (canceled)22. The solid dressing of claim 1 , wherein said haemostatic layer is composed of a plurality of particles ...

WOUND HEALING THROUGH SIRT1 OVEREXPRESSION

Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1. 1. A composition comprising a nucleic acid comprising a Sirt1 gene and a biocompatible polymeric carrier material.2. The composition of claim 1 , wherein the nucleic acid is embedded within the carrier material.3. The composition of claim 1 , wherein the nucleic acid is coated onto the carrier material.4. The composition of claim 1 , wherein the nucleic acid is released from the carrier when the carrier contacts an aqueous or physiologic environment.5. The composition of claim 1 , wherein the carrier degrades when it contacts an aqueous or physiologic environment.6. The composition of claim 1 , wherein the carrier comprises a polymeric network or hydrogel.7. The composition of claim 1 , wherein the carrier comprises a polyester claim 1 , polyurethane claim 1 , polycarbonate claim 1 , polyanhydride claim 1 , polyphosphoester claim 1 , or a mixture thereof.8. The composition of claim 1 , wherein the carrier comprises a citric acid polyester.9. The composition of claim 8 , wherein the carrier comprises poly(polyethyleneglycol co-citric acid-co-N isopropylacrylamide) (PPCN).10. The composition of claim 1 , wherein the Sirt1 gene is a synthetic sequence comprising at least 70% sequence identity with all or a portion of SEQ ID NO: 1.11. The composition of claim 1 , wherein the Sirt1 gene is a synthetic sequence and encodes a Sirtuin 1 polypeptide having at least 70% sequence ...

HAEMOSTATIC DEVICE

A bioresorbable haemostatic foam sponge for adhering to a wound. The sponge has a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements. Also disclosed are methods for forming the haemostatic sponge and methods of using the sponge. 1. A bioresorbable haemostatic foam sponge for adhering to a wound , the sponge having a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements , wherein the sponge is manufactured from collagen , starch , gelatin or hyaluronic acid.2. The haemostatic sponge according to claim 1 , wherein the tissue contacting elements are finger-like or columnar.3. The haemostatic sponge according to claim 1 , wherein each tissue contacting element has a depth of at least 2 mm.4. The haemostatic sponge according to claim 1 , wherein each tissue contacting element has a depth of 10 mm or less.5. (canceled)6. The haemostatic sponge according to claim 1 , wherein the depth of each tissue contacting element is 80% or less of the depth of the sponge.7. The haemostatic sponge according to claim 1 , wherein the cross-sectional shape of each tissue contacting element is substantially rectangular.8. The haemostatic sponge according to claim 1 , wherein each tissue contacting element has a cross-sectional area of 25 mmor less.9. (canceled)10. (canceled)11. The haemostatic sponge according to claim 1 , wherein the cross-sectional area of each tissue contacting element is substantially uniform.12. The haemostatic sponge according to claim 1 , wherein the maximum cross-sectional linear dimension of each tissue contacting element is 10 mm or less.13. (canceled)14. The haemostatic sponge according to claim 1 , wherein the maximum cross-sectional linear dimension is two times or less than the depth of the tissue contacting element.15. The haemostatic sponge according to claim 1 , wherein the tissue contacting elements are arranged such that each tissue contacting element is within at ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator and a solvent consisting of water , wherein said haemostatic layer is substantially homogenous , frozen , and substantially free of fibrin.2. (canceled)3. The solid dressing of claim 1 , further comprising at least one support layer.4. The solid dressing of claim 3 , wherein said support layer comprises a backing material.5. The solid dressing of claim 3 , wherein said support layer comprises an internal support material.6. The solid dressing of claim 3 , wherein said support layer comprises a resorbable material.7. The solid dressing of claim 3 , wherein said support layer comprises a non-resorbable material.8. The solid dressing of claim 7 , wherein said non-resorbable material is selected from the group consisting of silicone polymers claim 7 , paper claim 7 , gauze and latexes.9. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.10. The solid dressing of claim 6 , wherein said resorbable material is selected from the group consisting of proteinaceous materials and carbohydrate substances.11. The solid dressing of claim 10 , wherein said proteinaceous material is at least one substance selected from the group consisting of keratin claim 10 , silk claim 10 , fibrin claim 10 , ...

Multi-component electrospun fiber scaffolds

A scaffold may comprise a first polymeric electrospun fiber comprising a first material having a first degradation rate, and a second polymeric electrospun fiber comprising a second material having a second degradation rate different from the first degradation rate. The first degradation rate may substantially correspond to a cell infiltration rate, and the second degradation rate may be slower than the first degradation rate. Such a scaffold may be manufactured by electrospinning a first polymer fiber having a first degradation rate by ejecting a first polymer solution from a first polymer injection system onto a mandrel, and electrospinning a second polymer fiber having a second degradation rate different from the first degradation rate by ejecting a second polymer solution from a second polymer injection system onto a mandrel. Wound healing may be improved by applying such a scaffold to a portion of a wound.

Hemostatic Foam

The invention is directed a hemostatic foam, to a process for preparing a biodegradable hemostatic foam, and to the use of said foam. The hemostatic foam comprises a blend of a chitosan hemostatic agent and a polymer, which polymer provides the foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm. 1. A hemostatic foam comprising a blend of a chitosan hemostatic agent and a polymer , wherein said polymer provides said hemostatic foam with a porosity of 85-99% and a foam density of 0.01-0.2 g/cm , wherein said foam density is calculated as the polymer mass per volume unit foam.2. A hemostatic foam according to claim 1 , wherein the amount of said chitosan hemostatic agent is from 0.1 to 99 wt. % of the total weight of said hemostatic foam.3. A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent is present in said hemostatic foam in the form of particles.4. A hemostatic foam according to claim 3 , wherein said particles have a size from 1-1000 μm.5. A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent is chitosan or a chitosan salt.6. A hemostatic foam according to claim 1 , wherein said chitosan hemostatic agent has a degree of deacetylation of 1-100 mol %.7. A hemostatic foam according to claim 1 , wherein said polymer is selected from the list consisting of polyesters claim 1 , polyhydroxyacids claim 1 , polylactones claim 1 , polyetheresters claim 1 , polycarbonates claim 1 , polydioxanes claim 1 , polyanhydrides claim 1 , polyurethanes claim 1 , polyester(ether)urethanes claim 1 , polyurethane urea claim 1 , polyamides claim 1 , polyesteramides claim 1 , poly-orthoesters claim 1 , polyaminoacids claim 1 , polyphosphonates claim 1 , polyphosphazenes and combinations thereof.8. A hemostatic foam according to claim 1 , wherein said polymer is a phase-separated polymer comprising an amorphous segment and a crystalline segment claim 1 , wherein at least said amorphous segment comprises a hydrophilic ...

DEGRADABLE AND ABSORBABLE HEMOSTATIC FIBER MATERIAL, PREPARATION METHOD THEREFOR, AND HEMOSTATIC FIBER ARTICLE THEREOF

A degradable and absorbable hemostatic fiber material, a preparation method therefor, and a hemostatic fiber article thereof. The carboxylation degree of the hemostatic fiber material is 10-25%, and the polymerization degree of the hemostatic fiber material is 10-250. The hemostatic fiber material comprises fiber filaments, the linear density of the fiber filament being 0.8-4.5 dtex, and the dry strength of the fiber filament being 10-150 cN/tex. The degradable and absorbable hemostatic fiber material has a higher carboxylation degree and a lower polymerization degree, while the strength and completeness of the fiber filament can be well maintained, such that the hemostatic effect is better and the hemostasis is faster. Further, the hemostatic fiber material can be degraded and absorbed, and thus is safer. 1. A degradable and absorbable hemostatic fiber material , wherein the hemostatic fiber material has a degree of carboxylation of 10-25% , and a degree of polymerization of 10-250; the hemostatic fiber material comprises fiber filaments having a linear density of 0.8-4.5 dtex; and the fiber filaments have a dry strength of 10-150 cN/tex.2. The degradable and absorbable hemostatic fiber material of claim 1 , wherein the hemostatic fiber material has a maximum water absorption that is more than 10 times of the weight of the hemostatic fiber material.3. A hemostatic fiber product claim 1 , comprising the degradable and absorbable hemostatic fiber material of .4. The hemostatic fiber product of claim 3 , wherein more than 50% by quantity of the fiber filaments of the hemostatic fiber material have a length greater than 10 mm.5. The hemostatic fiber product of claim 3 , wherein the hemostatic fiber product comprises a fiber layer of the hemostatic fiber material.6. The hemostatic fiber product of claim 5 , wherein the fabric weight ratio per fiber layer is 1×10-8×10g/cm.7. The hemostatic fiber product of claim 3 , wherein the hemostatic fiber material in the hemostatic ...

HAEMOSTATIC DEVICE

A bioresorbable haemostatic foam sponge for adhering to a wound. The sponge has a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements. Also disclosed are methods for forming the haemostatic sponge and methods of using the sponge. 1. A bioresorbable haemostatic foam sponge for adhering to a wound , the sponge having a tissue-contacting surface divided into a plurality of closely-spaced tissue contacting elements , wherein the sponge is manufactured from collagen , starch , gelatin or hyaluronic acid.2. A haemostatic sponge according to claim 1 , wherein the tissue contacting elements are finger-like or columnar.3. A haemostatic sponge according to wherein each tissue contacting element has a depth of at least 2 mm.4. A haemostatic sponge according to claim 1 , wherein each tissue contacting element has a depth of 10 mm or less.5. (canceled)6. A haemostatic sponge according to claim 1 , wherein the depth of each tissue contacting element is 80% or less of the depth of the sponge.7. A haemostatic sponge according to claim 1 , wherein the cross-sectional shape of each tissue contacting element is substantially rectangular.8. A haemostatic sponge according to claim 1 , wherein each tissue contacting element has a cross-sectional area of 25 mmor less.9. (canceled)10. (canceled)11. A haemostatic sponge according to wherein the cross-sectional area of each tissue contacting element is substantially uniform.12. A haemostatic sponge according to claim 1 , wherein the maximum cross-sectional linear dimension of each tissue contacting element is 10 mm or less.13. (canceled)14. A haemostatic sponge according to claim 1 , wherein the maximum cross-sectional linear dimension is two times or less than the depth of the tissue contacting element.15. A haemostatic sponge according to claim 1 , wherein the tissue contacting elements are arranged such that each tissue contacting element is within at least 1 mm claim 1 , at least 0.5 mm or at ...

A Ready To Use Biodegradable And Biocompatible Device And A Method Of Preparation Thereof

The invention provides a ready to use biodegradable and biocompatible device and a method for manufacturing thereof. The device of present invention is a novel porous scaffold which can be used as carrier of plurality of therapeutics to quickly stop bleeding and other biomaterial and biomedical application. The scaffold can be directly applied to the spot of the wound and will stop bleeding within no time. The scaffold of the present invention comprises of combined application of air dry and freeze dry method. The scaffold also comprises of excellent ventilations properties and easy removal of the scaffold without causing any extra hemorrhage to the wound. 121-. (canceled)22. A biodegradable and biocompatible device having a porous micro-matrix structure comprising gelatin and chitosan in a 2:1 ratio , the gelatin and chitosan forming a polyelectrolyte complex , and the device being impregnated with a clotting agent , wherein the device does not contain a cross-linker.23. The device of claim 22 , wherein the clotting agent is selected from the group consisting of tranexamic acid claim 22 , calcium chloride claim 22 , thrombin and glucosamine.24. The device of claim 23 , wherein the clotting agent is tranexamic acid.25. The device of claim 22 , wherein the device consists of two porous faces claim 22 , one face having a pore size small enough to prevent the loss of blood components claim 22 , the other having a pore size large enough for blood cells to enter the device.26. The device of claim 22 , further comprising an adhesive backing or perforated sheet.27. The device of claim 22 , further comprising another therapeutic agent claim 22 , bioactive molecule claim 22 , or cell.28. The device of claim 27 , wherein the therapeutic agent is an antibiotic claim 27 , analagesic claim 27 , anti-allergic agent claim 27 , or antioxidant.29. The device of claim 27 , wherein the bioactive molecule is a clotting factor claim 27 , clotting co-factor claim 27 , or growth factor.29 ...

Extended Wear-Time Dressing

As an example, in some embodiments is a dressing that may comprise a manifold, a bioresorbable component, and a degradation-modulating component. The degradation-modulating component may cover two or more surfaces of the bioresorbable component. The degradation-modulating component may be further configured to modulate degradation of the bioresorbable component.

Antioxidant and antimicrobial wound dressing materials

A wound dressing material comprising a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may comprise collagen and/or oxidized regenerated cellulose complexed to Ag + , and the dyestuff may for example be an aniline or acridine dye. Also provided are methods of making such materials, and wound dressings comprising such materials.

Biodegradable graphene oxide biocomposite fibrous membrane, preparation method and uses thereof

The invention relates to a biodegradable graphene oxide biocomposite fibrous membrane and a preparation method and uses thereof. The composite fibrous membrane comprises biodegradable graphene oxide biocomposite fibers, each fiber has an outer layer consisting of graphene oxide-biodegradable polymer nanofibers and an inner layer consisting of sodium alginate/polyvinyl alcohol nanocomposite fibers. The biodegradable graphene oxide biocomposite fibrous membrane of the invention has the advantages of good biocompatibility, biodegradability, swellability, bacteriostasis and good mechanical properties and chemical stability.

OXIDIZED CELLULOSE-BASED MATERIAL, METHOD FOR OBTAINING SAME AND USE THEREOF AS COMPRESS

The present invention relates to a method of obtaining a solid material based on a polymer having its cellobiose units exhibiting the following characteristics: